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ABSTRACT OF THE DISSERTATION 
IR820 NANOCONJUGATES FOR THERANOSTIC APPLICATIONS 
by 
Alicia Fernandez-Fernandez 
Florida International University, 2013 
Miami, Florida 
Professor Anthony J. McGoron, Major Professor 
Near-infrared dyes can be used as theranostic agents in cancer management based on 
their optical imaging and localized hyperthermia capabilities. However, their clinical 
translatability is limited by issues such as photobleaching, short circulation times, and 
non-specific biodistribution. We studied the applications of IR820 in optical imaging and 
hyperthermia, and we prepared nanoconjugate formulations to overcome some of the 
aforementioned limitations. Free IR820 can be used for optical imaging, with a strong 
signal still present 24 hours after i.v. injection, an elimination plasma half-life in the 
order of hours, and primary biodistribution to liver, lung, and kidneys. After 808-mn laser 
exposure, IR820 can also raise in vitro temperatures to the 41-43°C range that can 
selectively inhibit cancer cell growth. We conjugated IR820 with PEG-diamine via ionic 
interactions to create nanoconjugates (IR820-PDNCs) with diameters of approximately 
50-nm per SEM and a zeta potential of 2.0±0.9 mV. IR820-PDNCs enhanced cellular 
internalization compared to IR820 for imaging in SKOV-3, MES-SA, and Dx5 cancer 
cells. The nanoconjugates also significantly enhanced hyperthermia-mediated 
cytotoxicity in MES-SA and Dx5 compared to the free dye (p<0.05). Covalent 
conjugation of IR820 with PEG-diamine for further stabilization resulted in 
viii 
 
nanoconjugates (IRPDcov) that have potential for in vivo applications. Our IRPDcov 
formulation retained the ability to fluoresce and to cause hyperthermia-mediated cell-
growth inhibition, with enhanced internalization and significantly enhanced cytotoxic 
hyperthermia effects compared to free dye. Additionally, IRPDcov demonstrated 
significantly longer (p<0.05) plasma half-lives, elimination half-lives, and area-under-
the-curve values compared to IR820, indicating larger overall exposure to the theranostic 
agent. The IRPDcov conjugate had different organ localization than free IR820, with 
potential reduced accumulation in the kidneys and significantly lower (p<0.05) 
accumulation in the lungs. Some potential advantages of IR820-PEG-diamine 
nanoconjugates may include passive targeting of tumor tissue through the enhanced 
permeability and retention effect, prolonged circulation times resulting in increased 
windows for combined diagnosis and therapy, and further opportunities for 
functionalization, targeting, and customization. The conjugation of PEG-diamine with a 
NIR dye provides a multifunctional delivery vector whose localization can be monitored 
with noninvasive techniques and that may also serve for guided hyperthermia cancer 
treatments. 
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CHAPTER 1: INTRODUCTION, LITERATURE REVIEW,                                       
AND SPECIFIC AIMS  
1.1. Background and Relevance 
1.1.1. The field of theranostics 
Advances in early cancer diagnosis and therapy have improved the survival statistics of 
individuals with cancer in the last few decades. Based on data collected 2001-2007, the 5-
year relative survival rate in cancer patients is 67%, which is 18% higher than thirty years 
ago (ACS, 2012). The use of multifunctional modalities which possess diagnostic and 
therapeutic properties, referred to as theranostics, can further enhance cancer 
management by enabling a combined approach to detection and treatment (Xie et al., 
2010). In many cases, early detection is the most important variable affecting the choice 
of therapeutic intervention and regimen. The timeline for detection of a tumor will impact 
the feasibility of surgical resection without the need for adjuvant treatment. In later stages 
of cancer, a combination of management approaches will be needed, which typically 
include surgery, radiation, and chemotherapy (Minev, 2011). 
 
One of the main challenges in combining early diagnosis and therapy is that imaging and 
therapeutic probes are typically different in terms of selectivity and biodistribution 
(Kelkar et al., 2011). This complicates the process of monitoring responses to treatment, 
which in turn creates difficulties in planning, timing, and assessing the success of 
interventions. By combining both therapy and diagnostic capabilities into a single 
platform, theranostic agents provide clinicians with a multipurpose tool that can be used 
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to detect, image, treat, and monitor therapeutic response over time (Sumer et al., 2008). 
As a result, clinicians can implement therapy at an earlier stage, as well as achieve 
increased safety, sensitivity and efficacy in heterogeneously natured diseases such as 
cancer (Melancon et al., 2012; Sumer et al., 2008). The ability to monitor disease 
progression in a more effective manner can also reduce delays in implementing plan of 
care changes when therapy regimes need to be adjusted.  
 
From the patient’s point of view, quality of care may be enhanced as well. Theranostic 
management strategies could minimize the need for repeated medical procedures that 
may involve multiple office visits or hospital stays, increased risk of side effects, 
increased risk of dosage or medical errors, delayed therapeutic interventions, discomfort, 
and impact on their psychological well-being and quality of life. 
1.1.2. Multifunctional agents used in theranostic applications: the advantages of 
nanomaterials 
Multifunctional approaches may be crucial to the development of customizable early 
detection systems, tailored cancer therapies, real-time monitoring of treatment 
progression, and clinically translatable advances in cancer diagnosis, intervention and 
prognosis (Fernandez-Fernandez et al., 2011).   Although the field of theranostics is still 
in its infancy in terms of development, there has been an explosion of research in this 
field in the past few years, in part related to parallel developments in nanotechnology. 
Many nanomaterials have built-in imaging capabilities, and can be modified to become 
multifunctional by combining them with a therapeutic agent via entrapment, conjugation, 
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or adsorption; or by exploiting their inherent therapeutic properties such as heat 
generation hyperthermia or singlet oxygen generation for photodynamic applications. 
Additionally, nanoparticles can circumvent some delivery challenges, such as those posed 
by multidrug resistance phenomena and in some cases by physiological barriers, such as 
the blood-brain barrier (Zamboni et al., 2012). 
 
The fact that both diagnosis and therapy require sufficient accumulation in target tissues 
is another reason why nanoformulations provide a desirable platform for theranostic 
purposes (Bharali et al., 2010; Xie et al., 2010). Due to their small size, nanoparticles are 
less susceptible to reticuloendothelial system clearance than larger agents, and for sizes 
around 100 nm with near neutral charge, they have better in vivo penetration into tissues 
and cells (Brigger et al., 2002; Xu et al., 2006). The enhanced permeability and retention 
effect (EPR) also provides nanosize vehicles with the inherent advantage of passive 
targeting to tumor sites (Iyer et al., 2006; Maeda, 2010; Maeda et al., 2000). When tumor 
tissues are compared to healthy tissues, research has found several anatomical and 
physiological differences, including larger pore sizes and increased leakiness, shape 
irregularities, and reduced lymphatic clearance (Kelkar et al., 2011). The end result is that 
there is preferential accumulation of nanoformulations in tumors due to enhanced 
delivery and reduced clearance from tumor tissues, which may translate into increased 
treatment efficacy and reduced systemic toxicity (Maeda et al., 2009; Maeda et al., 2000), 
although this approach is limited by its lack of true specificity. Another characteristic of 
many tumors is active angiogenesis, which increases blood vessel availability in the 
tumor area (Maeda, 2010). It is also possible to artificially enhance the EPR effect by 
4 
 
increasing regional blood pressure, or through the use of nitric oxide donors in the case of 
hypoxic tumors. Both of these approaches have been demonstrated to be successful in 
humans in increasing drug accumulation at target sites via nanocarriers (Maeda, 2010). 
Still, more specific approaches to deliver these formulations would be desirable, given 
that cancer is by definition a heterogeneous problem. 
 
To overcome the limitations of passive targeting, nanoformulations can be actively 
targeted by decoration or conjugation with moieties such as small ligands, antibodies, or 
biomarkers that can direct them towards specific molecular targets, resulting in increased 
selectivity and specificity of cellular uptake (Fernandez-Fernandez et al., 2011). 
Additionally, nanoformulations can be coated with different substances to provide 
specific desirable properties. An excellent example is coating of nanoparticles with 
polyethylene glycol (PEG), either via adsorption or covalent conjugation, to obtain 
stealth formulations and reduce biological elimination. PEG is a hydrophilic polymer that 
reduces non-specific interactions with proteins, which would lead to subsequent 
phagocytosis of the nanosystems by circulating immune system agents such as 
macrophages. The mechanism by which PEG exerts this function is primarily through 
steric repulsion as well as surface charge shielding effects, so that PEGylation results in 
long-circulating formulations (Bazile et al., 1995; Gref et al., 2000; Li et al., 2001; 
Moghimi et al., 2001; Peracchia et al., 1999; Scott et al., 1998). PEGylation also 
minimizes van der Waals attractions between particles, resulting in reduced aggregation 
behaviors that would lead to additional reticuloendothelial system recognition and 
elimination (Jokerst et al., 2011); and it also reduces metabolic degradation by enzymes 
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(Veronese et al., 2005). Covalent attachment of PEG chains does not affect chain 
properties in solution, so that formulations where PEG has been covalently attached will 
maintain their functionality (Alexis et al., 2008; Hrkach et al., 1997). PEGylation is 
considered a safe procedure for molecules destined for human use, with a therapeutic 
index of at least 600-fold between PEGylated products and PEG exposure levels that are 
toxic to humans (Webster et al., 2007). 
1.1.3. Multifunctional agents used in theranostic applications: image-guided therapy 
The imaging capability of a theranostic agent is often crucial for detection and 
monitoring purposes (Caldorera-Moore et al., 2011). Molecular imaging agents can be 
used as a diagnostic tool to visualize tissues and also to measure cellular processes related 
to disease. Nuclear imaging techniques such as PET and SPECT can provide valuable 
functional information, but have some disadvantages such as radiation exposure and 
complexity of the equipment (Janib et al., 2010). Optical imaging methods have high 
sensitivity, are inexpensive, and can be incorporated into fiber optic systems allowing for 
minimally invasive approaches; but they are limited by absorption and scattering, which 
result in low penetration (Alfano et al., 1997). This limitation can be alleviated by the use 
of near-infrared (NIR) imaging agents. At wavelengths between 700 and 900 nm, in vivo 
absorption and scattering processes are reduced due to decreased interaction with 
biological cromophores compared to shorter wavelengths of light (Simpson et al., 1998).  
This property results in improved tissue penetration for in vivo NIR optical imaging 
compared to optical imaging at shorter wavelengths (Bloch et al., 2005). 
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Nanoparticles have been used for applications involving MRI, CT, nuclear, and optical 
imaging (Kang, 2010; Lee et al., 2008), and multifunctional nanoparticle designs allow 
for simultaneous in vivo delivery of imaging and therapeutic agents (Kim et al., 2010). In 
some cases, the intrinsic properties of the nanoparticle allow it to be used as an imaging 
agent and/or an agent for hyperthermia, radiation, or photodynamic therapy applications. 
This provides opportunities for image-guided therapy and truly integrated theranostic 
systems (Fernandez-Fernandez et al., 2011).  
 
For example, iron-oxide nanoparticles can be used as MRI probes and as hyperthermia 
agents, and can also be loaded with chemotherapy agents to serve as drug delivery 
carriers (Wust et al., 2006; Yu et al., 2008). Gold nanoformulations such as nanospheres, 
nanorods, nanoshells, and nanocages have been applied to optical imaging, CT imaging, 
photothermal therapy, drug delivery, and combined imaging and therapy (Huang et al., 
2008; Huff et al., 2007; Oyelere et al., 2007; von Maltzahn et al., 2009). Silica-based 
formulations have also been applied for multifunctional purposes in combination with 
other agents. Benachour et al have recently reported the preparation of multifunctional 
silica-based nanoparticles with encapsulated chlorin for photodynamic therapy, and 
decorated with gadolinium to serve as an MRI contrast agent as well as with peptides for 
active targeting (Benachour et al., 2012). Some NIR dyes such as cyanine dyes, 
rhodamine-based formulations, phtalocyanine and napthalocyanine can also be used as 
photothermal and imaging agents (Bandichhor et al., 2006; Hilderbrand et al., 2005; 
Patonay et al., 2004). Cyanine dyes have large molar extinction coefficients, mid-range 
fluorescence quantum yields, and a wide choice of tunable wavelengths (Hilderbrand et 
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al., 2005; Patonay et al., 2004; Zaheer et al., 2001), which makes them attractive for in 
vivo applications.  
1.1.4. The cyanine dyes indocyanine green and IR820 and their applications in imaging  
and hyperthermia 
An example of a cyanine NIR dye with multifunctional applications is indocyanine green 
(ICG), which has been utilized for many years in clinical measurement of cardiac output, 
evaluation of liver and kidney function, photodynamic therapy, photothermal therapy and 
imaging (Dorshow et al., 1998; Johansen, 1990), and has low toxicity. Upon excitation by 
light, ICG can release energy as emitted fluorescence photons, as well as through non-
radiative internal conversion and heat emission. Although the heat generation efficiency 
of ICG is smaller than that of gold nanoparticles (Hirsch et al., 2003; O'Neal et al., 2004), 
ICG is able to rapidly elevate temperature upon laser excitation to therapeutic thermal 
ranges that can selectively kill cancer cells (Abels et al., 2000; Chen et al., 1996; Tang et 
al., 2009). Hyperthermia has been widely utilized as an adjuvant treatment for cancer 
(Luk et al., 1980; van der Zee, 2002), and is less prone to toxic side eﬀects than other 
therapeutic approaches such as chemotherapy (Kelkar et al., 2011). Cell culture, animal 
and human studies have also shown that hyperthermia has a synergistic effect with other 
cancer therapeutic modalities (Fotopoulou et al., 2010; Tang et al., 2009; West et al., 
1980; Wust et al., 2002). 
 
The main challenge of using ICG in vivo is its poor stability in aqueous solution and fast 
degradation rates, as well as its very short plasma half-life in the order of 3 to 5 minutes 
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(Desmettre et al., 2000; Haller et al., 1993; Saxena et al., 2003). This limits the in vivo 
therapeutic window for hyperthermia, imaging, or a dual combination using ICG, 
especially in the case of the combinational approach, where timing of the diagnostic and 
the therapeutic components may be an issue. In order for a multifunctional approach to be 
effective and clinically translatable, the combined diagnostic and therapeutic windows 
have to be large enough to make both processes practically feasible. If the window of 
opportunity is very short, it becomes very difficult to use the diagnostic information to 
guide therapy, or to follow the effects of therapy during a subsequent monitoring period.  
Since the main mechanism of fluorescence degradation in ICG is the formation of 
weakly-fluorescing ICG aggregates via intermolecular interactions (Zhou et al., 1994), 
some groups have attempted to increase the stability of ICG using stabilizer additives 
such as the Poly-(α,β)-DL-aspartic acid sodium salt PASP (Maarek et al., 2001; 
Rajagopalan et al., 2000). However, the additive can complicate the incorporation of the 
dye into delivery vehicles such as nanoparticles, and its toxicity profile for in vivo use has 
not been adequately evaluated.   
 
Nanoformulations of ICG, such as ICG-loaded PLGA nanoparticles or ICG-loaded 
mesocapsules have demonstrated increased plasma circulation times and organ uptake in 
mice (Saxena et al., 2006; Yaseen et al., 2009). Our group has shown that ICG entrapped 
in nanoparticles can still produce hyperthermic cell killing (Tang et al., 2010), and we 
have developed a multifunctional ICG-DOX-PLGA delivery system for image-guided 
chemotherapy and hyperthermia (Manchanda et al., 2010). When exploring the effect of 
the multifunctional system in cancer cell lines MES-SA, DX-5, and SKOV-3, we found 
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that this delivery vehicle was able to circumvent multidrug resistance  (MDR) in resistant 
cells which expressed p-glycoprotein, and that the combination of hyperthermia and 
chemotherapy resulted in improved cell killing compared to chemotherapy or 
hyperthermia alone (Tang et al., 2010). 
A possible alternative to the use of ICG, either in free dye form or as a nanoformulation, 
is to explore the potential of other NIR dyes with similar optical and thermal generation 
abilities but improved stability profiles. It would be desirable to have the ability to use 
NIR-responsive molecules for imaging and hyperthermia while eliminating or 
minimizing some of the problems that complicate ICG in in vivo applications (Fernandez-
Fernandez et al., 2012). An example of a NIR dye with strong similarities to ICG is the 
commercially available dye IR820. The chemical structures of ICG and IR820 are very 
similar, with the main difference being the addition of a chlorinated cyclohexene as an 
intermediate ring in the structure of IR820 (Figure 1).  
 
 
Figure 1. Molecular structures of indocyanine green (A) and IR820 (B). Note the structural similarity, 
except for the chlorinated cyclohexene ring structure in IR820 which is absent in ICG. 
 
The presence of this ring is expected to confer additional rigidity and stability to the 
molecular structure compared to ICG, given that substituents within the polymethine 
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chain will limit bond rotation (Levitus et al., 2011). The structural modification could 
also possibly result in enhanced molecular stability by providing steric hindrance to 
intermolecular aggregation processes. An additional advantage of the presence of the 
chlorohexene is that it provides IR820 with more options for functional conjugation 
through the chlorine group, which can result in more amenability to the creation of 
multifunctional or targeted conjugates.    
 
Several recent studies have applied IR820 dye or conjugates of the dye for in vivo 
applications. Prajapati et al. used IR820 as a blood pool contrast agent to image tissue 
injuries and tumors in mice, and estimated the dye clearance half-life to be similar to that 
of albumin, approximately 35 hours, based on in vitro binding studies to albumin 
(Prajapati et al., 2009). Pandey et al. conjugated IR820 with a photodynamic therapy drug 
and studied the resulting conjugate in mice with IR820 being used exclusively for its 
imaging role (Pandey et al., 2008). Masotti et al. conjugated IR820 with 
polyethylenimine (PEI) for DNA binding applications and in vivo imaging (Masotti et al., 
2008). Thierry et al prepared poly(allylamine hydrochloride)-poly(acrylic acid) coated 
magnetic iron oxide and gold nanoparticles, which were loaded with cisplatin as well as 
with a conjugate of IR820 and PEI following the work done by Masotti and colleagues 
(Thierry et al., 2009).   
 
None of these studies exploited the inherent ability of IR820 to be used as a dual imaging 
and hyperthermia agent, with all of them just focusing on its imaging properties. Prior to 
our group’s work, there were also no previous reports of any efforts to perform a detailed 
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in vitro characterization of IR820 in terms of thermal generation and optical 
characteristics, or to study its toxicity in cellular systems, which should all have preceded 
any in vivo applications (Fernandez-Fernandez et al., 2012). Additionally, there are to our 
knowledge no reports of nanoconjugates of IR820 except for those resulting from this 
dissertation. 
1.2. Statement of Purpose and Specific Aims 
The overarching goal of this project was to develop and characterize novel 
nanoconjugates of IR820, and explore the potential of IR820 and its conjugates for 
theranostic applications in cancer. As a result of the studies which are part of this 
dissertation, our group was the first to characterize IR820 in terms of optical and thermal 
generation properties; to compare IR820 properties to those of ICG for cellular 
hyperthermia, cellular imaging, and in vivo imaging; and to formulate and characterize 
long-circulating nanoconjugates of IR820 and polyethylene glycol (PEG) for theranostic 
applications.   
 
The following were the four objective-based specific aims: 
1.2.1. Specific aim #1: IR820 in vitro characterization and theranostic applications 
a. Characterize the in vitro absorption and fluorescence behavior of IR820, and 
compare it with ICG. 
b. Characterize the degradation of IR820 in aqueous solution under different 
light and temperature conditions, and compare degradation kinetics with 
those of ICG.  
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c. Compare in vitro cell imaging capabilities of IR820 with those of ICG. 
d. Compare the in vitro heat generation capability of IR820 after NIR laser 
exposure with that of ICG. 
e. Characterize the in vitro cytotoxicity of IR820 on cancer cell lines MES-SA, 
SKOV-3, and Dx5, and compare with ICG. 
f. Characterize the in vitro cytotoxicity of IR820 on cancer cell lines MES-SA, 
SKOV-3, and Dx5 after NIR laser exposure, and compare with ICG. 
Specific aim #1 is addressed in Chapter 3. 
1.2.2. Specific aim #2: Formulation and characterization of ionic IR820 nanoconjugate 
a. Prepare IR820-PEG-diamine nanoconjugate using ionic interactions (IR820-
PDNCs) 
b. Characterize IR820-PDNCs in terms of physicochemical properties, dye 
content, absorption/fluorescence properties, and stability in solution. 
c. Compare in vitro cell imaging capabilities of IR820-PDNCs with those of 
IR820. 
d. Characterize the in vitro cytotoxicity of IR820-PDNCs on cancer cell lines 
MES-SA, SKOV-3, and Dx5, and compare with IR820. 
e. Characterize the in vitro cytotoxicity of IR820-PDNCs on cancer cell lines 
MES-SA, SKOV-3, and Dx5 after NIR laser exposure, and compare with 
IR820.  
Specific aim #2 is addressed in Chapter 4. 
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1.2.3. Specific aim #3: Formulation and characterization of covalent IR820 
nanoconjugate 
a. Prepare covalently-linked IR820-PEG-diamine nanoconjugate (IRPDcov) 
b. Characterize IRPDcov in terms of physicochemical properties, dye content, 
absorption/fluorescence properties, and stability. 
c. Compare in vitro cell imaging capabilities of IRPDcov with IR820. 
d. Characterize the in vitro cytotoxicity of IRPDcov on cancer cell lines MES-
SA, SKOV-3, and Dx5, and compare with IR820. 
e. Characterize the in vitro cytotoxicity of IRPDcov on cancer cell lines MES-
SA, SKOV-3, and Dx5 after NIR laser exposure, and compare with IR820 
cytotoxicity. 
Specific aim #3 is addressed in Chapter 5. 
1.2.4. Specific aim #4: Biodistribution studies of IRPDcov, IR820, and ICG 
a. Establish feasibility of using IRPDcov for in vivo imaging. 
b. Compare and contrast the biodistribution of IRPDcov, IR820, and ICG in an 
in vivo model, using Matlab image analysis of fluorescent organ images 24 
hours after i.v. injection. 
c. Compare and contrast biodistribution of IRPDcov, IR820, and ICG in an in 
vivo model, by determining 24-hour quantitative content from organ 
sampling. 
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d. Calculate and compare IRPDcov, IR820, and ICG pharmacokinetic 
parameters, including plasma half-life, from blood sampling data collected at 
4 different time points after i.v. injection. 
Specific aim #4 is addressed in Chapter 6. 
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CHAPTER 2: METHODOLOGY  
This chapter describes the materials, methods, and protocols used in the experiments for 
each of the specific aims. Some of the descriptions in this chapter have been previously 
published as part of two manuscripts (Fernandez-Fernandez et al., 2012; Manchanda et 
al., 2012). Permission has been obtained in writing from the journal editors to utilize 
content from these publications in the dissertation manuscript, and copies of the 
aforementioned permission emails are included in the appendices. 
2.1. Materials and Methods for Specific Aim 1  
2.1.1. Chemicals  
ICG (MW 775, IR-125) was obtained from Fisher Scientific (Pittsburgh, PA). IR-820 
(MW 849.47), methanol, formaldehyde, and dimethyl sulfoxide (DMSO) were purchased 
from Sigma (St. Louis, MO).  
2.1.2. Absorbance studies  
Dye solutions were prepared in deionized water or in methanol and samples were placed 
in 1.5 mL cuvettes. Samples were diluted down to the linear absorption range (< 3 A.U.), 
and absorption spectra from 200 to 900 nm were recorded using a CaryWinUV 
spectrophotometer (Varian/Agilent Technologies, Switzerland). Automatic blank 
correction was performed using the appropriate solvent (water or methanol). The 
instrument was allowed to warm up for 30 minutes before measurements, and operating 
conditions were kept constant for all experiments. 
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2.1.3. Fluorescent spectrum characterization  
We prepared ICG and IR-820 solutions in deionized water at 20 μg/mL concentration, 
and then performed serial dilutions to 0.078 μg/mL. The fluorescence spectrum of each 
sample was measured using a Fluorolog-3 spectrofluorometer (Jobin Yvon Horiba, 
Edison, NJ) in steady-state mode. The device was allowed to warm up for 30 minutes, 
and then calibrated following manufacturer specifications for both the xenon lamp source 
and the expected Raman spectrum of water. Samples were placed in 4.5-mL cuvettes and 
measured immediately after preparation. For ICG and IR820 samples, we measured 
emission after excitation at 785-nm, because this is the wavelength that is typically used 
in ICG imaging systems. For IR820, we performed an additional set of measurements in 
which we used the peak absorption wavelength for IR820 in water as the excitation 
wavelength. We recorded spectral emission readings up to 900 nm, in 1-nm intervals. 
Deionized water was used as a blank for background correction.  The samples were 
handled under reduced lighting conditions at all times to avoid photobleaching. 
2.1.4. Effects of temperature and light on stability in aqueous solution 
In order to characterize the optical stability of ICG and IR-820 in aqueous solution, we 
prepared solutions of ICG and IR-820 as described in section 2.1.3., and selected a 
concentration in the linear range, specifically, 0.625 μg/mL. Each sample (ICG or IR820) 
was aliquoted into five borosilicate glass containers and each container was assigned to 
one of five groups: (1) room temperature with constant direct light, (2) room temperature 
covered with foil, (3) room temperature in the dark, (4) refrigerator, or (5) covered water 
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bath at 42°C. A sample from each container was taken and measured at twenty-four hour 
intervals, following the same calibration and measurement procedure. Measurements of 
fluorescent intensity at the peak emission were done in triplicate. The instrument 
operating conditions were kept constant throughout the four-day period.  
 
Data analysis followed the procedure described by Saxena et al in their study of ICG 
degradation in aqueous solution (Saxena et al., 2003). Briefly, data were plotted as 
percent peak fluorescence remaining versus time in hours, and fit to a pseudo-first order 
kinetics model to obtain the observed degradation rate constant kobs. From this, the 
corresponding degradation half-time was calculated as shown in Equation 1 below.  
 
   
obsk
ln(2) =t1/2   Equation 1 
2.1.5. Stability in different solvents under constant light and temperature conditions 
The stability of ICG and IR820 dissolved in DMSO or methanol over a period of four 
days was studied by selecting a concentration in the linear range, specifically, 0.312 
μg/mL, and placing a sample of each solution (ICG or IR820) at the chosen concentration 
in a borosilicate glass container in the refrigerator at 4°C in the dark. Samples from each 
container were measured at twenty-four hour intervals, following the same measurement 
procedure detailed in section 2.1.4., but using methanol or DMSO as the calibration blank 
as appropriate. Measurements were done in triplicate. The instrument operating 
conditions were kept constant throughout the four-day period.  
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2.1.6. Heat Generation Properties 
A NIR Laser Module source (RLDH808-1200-5, Roithner Laserthchnik Gmbh, Vienna, 
Austria) emitting at 808 nm with an output power of 1.0 Watts was used for the heat 
generation studies. Details of the setup have been provided by Tang et al. (Tang et al., 
2009). Briefly, the laser module was fixed to a clamp to direct NIR light from above. A 
heated stage insert (World Precision Instruments Inc, Sarasota, Florida) was placed on a 
mobile stage positioned directly below the laser, and used to keep a 96-well plate 
containing dye samples at a baseline temperature of 37°C. The laser, when operational, 
was enclosed in a box to prevent external emission of the NIR light and to avoid air 
circulation that would affect the temperature of the sample. The mobile stage (holding the 
heated insert) had an extension arm to the outside of the box. The arm was used to move 
the location of the well plates, thereby allowing individual wells to be exposed to the NIR 
energy in succession one at a time without opening the box. We prepared 2.5 μM, 5 μM, 
and 10 μM solutions of ICG and IR820. Each sample was added to three wells in a 96-
well plate sitting on the heated stage insert, and excited with the 808-nm laser at a power 
of 1440 J/cm2 for 180 seconds. Temperature inside the well was measured with a 
thermocouple for the duration of exposure, and the three well values for a given dye were 
averaged.  
2.1.7. Cytotoxicity with and without hyperthermia 
The cytotoxic effect of ICG or IR820 with and without laser treatment was studied in 
human ovarian carcinoma SKOV-3 cells, human uterine sarcoma MES-SA cells, and 
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resistant human uterine sarcoma MES-SA/Dx5 (Dx5) cells. MES-SA is a chemotherapy 
sensitive uterine sarcoma line, and Dx5 is its multidrug-resistant counterpart. Multi drug 
resistance (MDR) in Dx5 cells is conferred by expression of membrane drug efflux 
protein P-gp. The ovarian epithelial adenocarcinoma line SKOV-3 also shows MDR 
properties, but in this case due to an inherent p53 deletion gene mutation. Therefore, 
these cell lines may respond differently to targeted therapy and hyperthermia, and they 
provide good models for testing of cancer treatment modalities. The cell lines, along with 
McCoy’s 5A medium and fetal bovine serum (FBS) were purchased from ATCC 
(Manassas, VA, USA). Dulbecco's Phosphate Buffered Saline (DPBS) and penicillin 
were purchased from Sigma Aldrich.  
The cells were cultured as monolayers in McCoy's 5A medium supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin in a humidified atmosphere of 95% air and 
5% CO2 at 37°C. For continuous culturing, cells were grown in plastic tissue culture 
flasks, subcultured twice weekly, and used for experiments while in the exponential 
growth phase. In the cytotoxicity experiments, cells were seeded into two 96-well plates, 
labeled plate A and B, at 5,000–8,000 cells per well. The plates were incubated overnight 
to allow for cell attachment.  
 
On day 0, 24 hours after initial cell seeding, the cells in plate A were fixed and a 
Sulphorhodamine B (SRB) assay was performed using a TECAN plate reader (TECAN 
Systems Inc, San Jose California) at a wavelength of 530 nm to determine control growth 
of untreated cells. The absorbance values of the wells containing the cells were 
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background subtracted (from wells containing medium only) and averaged to give T0, 
defined as the initial amount of cells on day 0. Thus, plate A establishes a reference for 
the number of cells at the same time the experimental treatment is introduced in plate B.  
 
On day 0, at the same time plate A was fixed to provide the T0 value, plate B was treated 
with IR820 or ICG (final concentration of 0-10 µM). A final concentration of 0 µM 
indicates that no dye was added to the wells.  Next, the cells in plate B were incubated at 
37°C for approximately 2 hours, after which half of the wells in plate B were subjected to 
laser treatment for three minutes. For each concentration of dye (0-10 µM), half of the 
wells received laser treatment. Thus, for the control cells where no dye was added, half of 
the cells were exposed to laser. This provides a laser, no-dye control group. Plate B was 
returned to a 37°C incubator for another 24 hours. On day 1 (i.e. 48 hours after initial cell 
seeding and 24 hours after laser treatment), the cell protein amount was measured by the 
SRB assay. Potential cross talk between wells was eliminated by not using adjacent wells 
for cells that were exposed to laser treatment, thus ensuring that applying laser treatment 
to one well would not cause a temperature increase in another well. The SRB absorbance 
values were background subtracted to give T (absorbance of the treated cells) and C 
(absorbance of control cells not exposed to laser or dye). All measurements were done in 
four wells per treatment.  
 
The following formulae were used to calculate net cell growth:  
if T≥T0, net cell growth = (T-T0)/(C-T0);                                          Equation 2 
if T<T0 then net cell growth (or cell death) = (T-T0)/(T0).                Equation 3 
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T0 is determined from SRB measurements in plate A, and represents the number of cells 
at the time treatment was initiated.  C is determined from SRB measurements in plate B 
for the wells that were not exposed to either laser or dye, and T is the absorbance of the 
treated wells (laser treatment, dye treatment, or both). Net growth was plotted against dye 
concentration to show the toxicity effects as previously described in the literature (Monks 
et al., 1991). Statistical analysis (α = 0.05) was performed using one-way ANOVA to 
compare (1) treatment values with the control value and (2) laser treatment versus no 
treatment for the same concentration of dye (0-10 μM).  
2.1.8. Cellular imaging 
SKOV3, MES-SA, and Dx5 cell lines were purchased from ATCC and cultured 
following ATCC specifications with 10% FBS-supplemented McCoy's 5A medium in a 
37°C humidified incubator at 5% CO2 level.  D-poly coverslips, formalin and 24-well 
tissue culture plates were purchased from Fisher Scientific (Pittsburgh, PA, USA). Cells 
were seeded at a density of 4 x 104 cells per well (SKOV-3) or 1 x 105 cells per well 
(MES-SA, Dx5) in a 24-well plate over Poly-D-Lysine pre-coated glass coverslips placed 
in each well, and incubated overnight to reach confluence. The medium was removed and 
replaced with 0.5 mL of 10 μM IR820 or ICG solution and incubated for 30 minutes at 
37°C without light exposure.   
 
After incubation, cells were washed 3X with DPBS and fixed with 4% formaldehyde for 
15 minutes at 37°C, followed by 3X washing with DPBS. The coverslips were then 
removed and mounted on precleaned glass microslides with prolong antifade 
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reagent/mounting medium mixture. Then, the specimens were observed using a 
fluorescent microscope (Olympus IX81, Japan) with a 60x water immersion objective 
and images were recorded with a CCD camera. The same filter set (λex = 775nm and 
λem = 845nm) was used for imaging of both fluorescence dyes. The CCD camera 
settings and exposures times were the same for both dyes for a given cell line (1000 ms 
for SKOV-3 and 4000 ms for MES-SA and Dx5). Green pseudo-color was added using 
EZ-C1 software (Nikon, Melville, NY). 
2.1.9. Rat model studies 
An imaging system consisting of a Sanyo DL 7140-201S laser (80 mW, 785 nm) and a 
Retiga 1300 CCD camera was used. The entire setup was covered by BK5 blackout 
material. The power at the imaging plane ranged from 0.1-0.5 mW. An equimolar 
solution of ICG or IR820 was prepared based on a dose of 0.24 mg/kg of body weight 
(Rajagopalan, 2000) and an injection volume of 0.25 mL. Wistar rats (160-224 g, nine 
weeks old) were purchased from Harlan (Indianapolis, IN), kept under standard housing 
conditions and fed ad libitum. All protocols followed the regulations of the Institutional 
Animal Care and Use Committee. Rats were randomly assigned to groups. On the day of 
the experiment, the animals were first anesthetized by inhalation of isoflurane in a closed 
chamber, and then injected intraperitoneally with a 40 mg/kg dose of pentobarbital. The 
chest and abdomen were shaved, and the animal was placed in supine facing the imaging 
setup. An image of the rat was obtained under white light illumination to determine the 
position of the target and to focus the camera before dye injection. Then, the laser was 
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turned on and another image was taken prior to dye injection to establish background. 
Laser current was set to 60 mA.  
 
After the white and background images were obtained, ICG or IR820 dye was injected 
through the tail vein using a 3-way stopcock system connected to two syringes, one 
containing the dye and another one containing saline solution to flush the tail vein after 
injection. The camera started recording immediately before the injection, and 10-second 
exposure images of the abdomen were recorded in series using QCapture Pro software for 
at least 40 minutes or until the rat regained consciousness. An image focused on the chest 
was also taken before removing the animal from the setup on the day of the injection. 
Twenty four hours later, the rat was imaged again (abdomen and chest) using the same 
imaging setup under the same operating conditions. The protocol was completed in 6 rats, 
three per dye. Additionally, organs were carefully dissected and extracted after the 24-
hour imaging protocol was completed in the intact animal. The lungs, kidneys and liver 
were then placed in black-coated Petri dishes and imaged using the same imaging setup. 
 
Images were processed in Matlab to select a background-subtracted region of interest and 
calculate the normalized intensity, R, as the ratio of total pixel intensity (pixel index) in 
the region of interest to the area of the signal in μm2. Statistical analysis was performed to 
compare average ratios for each dye (t-test, 95% confidence level) 
 
Quantitative measurements were performed by dye extraction in DMSO following the 
procedure detailed by Saxena et al for ICG (Saxena et al., 2006). Briefly, the organs were 
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homogenized and then incubated for four hours in DMSO. After four hours, the samples 
were centrifuged at 4,500 rpm for 5 minutes, the supernatant was collected, and sample 
emission was measured in a spectrofluorometer after 785 nm excitation. Dye mass in μg 
obtained from this measurement was normalized to homogenized organ mass in grams, 
and statistical analysis was performed to determine significant differences in dye content 
(t-test at 95% confidence level). Dye mass was determined from a standard calibration 
curve.  
2.2. Materials and Methods for Specific Aim 2 
2.2.1. Chemicals  
PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide (DMSO > 99.9% reagent 
grade) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
2.2.2. Nanoconjugate preparation  
To an aqueous solution of PEG-diamine (MW 6 kDa, 30 mg/5 ml), a solution of IR820 
(8.4 mg/5 ml) dissolved in deionized water was added drop-wise over a period of 45 
minutes through a 5-ml syringe with continuous stirring. The molar ratio was 1:2 PEG-
diamine:IR820 based on available functional groups (two amines in PEG-diamine and 
one sulfonate in IR820). The reaction mixture was allowed to stir at room temperature for 
3 hours. The ionic complex between PEG-diamine and IR820 was achieved by 
electrostatic interactions between the negatively charged sulphate groups of IR820 and 
the positively charged amine groups of PEG-diamine (Figure 2). The solution was 
centrifuged at 25,000 rpm for 30 minutes, the supernatant was discarded, and the 
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nanoconjugates thus formed were washed 3x with deionized water (5 ml). The resulting 
material was freeze-dried using the Freezone system (Labconco, Free Zone Plus 6) for 24 
hours. 
                                                                                 
Figure 2. Reaction scheme and formulation of ionic IR820-PEG-diamine nanoconjugate (IR820-PDNCs).  
2.2.3. Nanoconjugate characterization 
Scanning electron microscopy (SEM) was used to verify size and uniformity of nanoplex 
shape and size. Freeze-dried IR820-PDNCs were resuspended in distilled water and were 
later dropped onto a silicon grid and dried under room temperature. The suspension was 
vacuum-coated with gold for 3 minutes. The surface morphology of the samples was 
observed under a scanning electron microscope (JEOL–JEM) operated at 15-keV pulse at 
different resolutions.  
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Nanoconjugate zeta potential was measured using a Zetasizer, Nano ZS (Malvern 
Instruments, UK) employing a nominal 5-mW He–Ne laser operating at 633 nm 
wavelength. The scattered light was detected at a 135° angle. The refractive index (1.33) 
and the viscosity (0.89) of ultrapure water at 25°C were used for measurements.  
 
The FTIR spectra of dried material was recorded using the Perkin–Elmer®Spectrum™ 
1000 FT-IR spectrometer (Perkin Elmer Inc., San Jose, CA), equipped with a 
Universal ATR (attenuated total reflectance) sampling device containing diamond crystal. 
Spectra were acquired and then processed with the Spectrum software. The spectra were 
scanned at room temperature over the wave number range of 4000–400 cm−1, with a scan 
speed of 0.2cm/s and accumulations at a resolution of 4 cm-1. Triplicates of each sample 
were averaged to obtain an average spectrum. A background spectrum of air was scanned 
under the same instrumental conditions before each series of measurements. 
2.2.4. Dye content determination 
The IR820 content in the freeze-dried nanoconjugates was determined by dissolving a 
known amount of sample in DMSO, sonicating to ensure complete dissolution, and 
performing serial dilutions in the fluorescence linear range. Sample fluorescence was 
measured at peak emission after 785-nm excitation with a Fluorolog-3 spectrofluorometer 
(Jobin Yvon Horiba, Edison, NJ, USA) under constant operating conditions. The amount 
of IR820 in the samples was determined from a calibration curve of free IR820 in DMSO 
after 785-nm excitation using blank subtraction. 
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2.2.5. Characterization of absorption properties 
We prepared samples of IR820, PEG-diamine, and IR820-PDNCs in deionized water at 
100 μg/mL concentration, and performed serial dilutions in the linear range. The 
concentration of IR820-PDNCs was normalized to dye content, and the concentration of 
PEG-diamine was also normalized based on the corresponding proportion of IR820 and 
PEG-diamine used in the formulation process. Sample absorption from 200 to 900 nm 
was measured with a Cary UV spectrophotometer (Varian/Agilent Technologies, 
Switzerland). 
2.2.6. Characterization of fluorescence properties 
We prepared samples of IR820 and IR820-PDNCs in PBS buffer at 100 μg/mL 
concentration, and performed serial dilutions in the linear range. Fluorescence emission 
from the samples was measured in 1-nm intervals after 690 nm-excitation, 785-nm 
excitation, and 844-nm excitation. Samples were measured using a Fluorolog-3 
spectrofluorometer (Jobin Yvon Horiba, Edison, NJ, USA). Fluorescent curves were 
blank-subtracted and plotted versus emission wavelength. 
2.2.7. Fluorescence stability studies 
We prepared samples of IR820 and IR820-PDNCs in PBS buffer at concentrations in the 
linear range, and measured their baseline fluorescence emission profile after 785 nm 
excitation. Sample emission fluorescence was measured from 795 nm up to 850 nm, at 1- 
nm intervals. The samples were measured in 4-mL cuvettes using a Fluorolog-3 
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spectrofluorometer (Jobin Yvon Horiba, Edison, NJ, USA). Different aliquots from the 
same sample batch were kept in the refrigerator and measured following the same 
procedures 4 hours after preparation. The emission peak value was used to determine 
changes from baseline and the percent remaining fluorescence intensity was calculated. 
Statistical significance was determined by comparing percent remaining intensities using 
a t-test with α = 0.05. 
2.2.8. Cytotoxicity with and without hyperthermia 
The cytotoxicity of four different treatments (IR820, IR820-PDNCs, IR820 plus laser, 
and IR820-PDNCs plus laser) in cancer cell lines was studied using the SRB colorimetric 
assay.  Three different types of cancer cell lines (MES-SA, Dx5 and SKOV-3) were used 
for cytotoxicity assessment.  Cells were seeded onto 96-well plates at an approximate 
density of 2x104 cells/well, and incubated overnight for attachment to the well, followed 
by treatment with free IR820 or IR820-PDNCs.  The SRB assay was performed 24 hours 
post treatment to determine net cell growth. Tested IR820 concentrations ranged from 0 
to 5 µM, where IR820 concentration equal to zero means that only DPBS and no drug 
was added to the wells (control group). Tested IR820-PDNCs concentrations were 
normalized to IR820 content in the particles so that the treatments were equivalent to 
tested concentrations of free dye.  
 
In order to test the effect of hyperthermia, some of the cells were incubated for one hour 
with one of the following treatments: (1) 5 μM IR820, (2) IR820-PDNCs at 
concentrations equivalent to 5 μM of IR-820, (3) 2.5 μM PEG-diamine (based on the 
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molar ratio 1 PEG-diamine: 2 IR820 in the nanoplex formulation), or (4) only cell 
medium. These cells were then exposed to NIR laser illumination for 3 minutes, and the 
SRB assay was performed 24 hours post laser treatment. Temperature was measured with 
a thermocouple, and experimental wells were separated from each other by at least one 
empty well in all directions to avoid cross-effects. Data processing and analysis were as 
described in section 2.1.7., with net growth values generated by normalizing the data 
from each treatment to the growth of the control cells which were not exposed to IR820, 
IR820-PDNCs, or laser. Statistical significance was identified by one-way ANOVA for 
the difference among groups at the same treatment concentration, and between each 
group and the control group. A p-value <0.05 was considered to be statistically 
significant. 
2.2.9. Cellular imaging 
Lysine-coated coverslips were placed in each well of a 24-well plate. MES-SA, Dx5, and 
SKOV-3 cells were seeded on the coverslip at a density of 1 × 105 cells, 1 × 105 cells and 
5 × 104 cells per well respectively in McCoy’s 5A medium supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin, and were grown overnight for attachment.  On the 
next day, the cell medium was removed and replaced with 5μM IR820 or equivalent free 
dye content of IR820-PDNCs. Cells were incubated in the dark at 37° C for 2.5 hours and 
then washed 3X with Dulbecco's phosphate buffered saline (DPBS). Then the cells were 
fixed with 4% formaldehyde for 15 minutes at 37°C, followed by 3X washing with 
DPBS. The coverslips were then removed and mounted on glass microslides with 
antifade reagent/mounting medium mixture. The cells were then examined by 
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fluorescence microscopy (Olympus IX81, Japan) with a 60X water-merged objective. 
The fluorescence was imaged at λex (775 nm), λem (845 nm) with an exposure time of 
4000 ms, which is well below the 20,000 ms threshold for autofluorescence. A CCD 
camera was used to capture the signals and the images were software-merged with 
pseudo color. The fluorescence microscope settings were kept the same throughout the 
experiment. Images were processed in Matlab to select a background-subtracted region of 
interest and to calculate the normalized intensity, R, as the ratio of total pixel intensity 
(pixel index) to signal area. 
2.3. Materials and Methods for Specific Aim 3 
2.3.1. Chemicals  
PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide (DMSO > 99.9% reagent 
grade), and triethylamine (TEA) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  
2.3.2. Nanoconjugate preparation 
A mixture of PEG-diamine (MW 6 kDa, 30 mg/5 ml) and IR820 (9.4 mg/5 ml) in 
methanol was refluxed for 4 hours in the presence of triethylamine (2 eq.). The molar 
ratio was 1:2 PEG-diamine:IR820 based on available functional groups (two amines in 
PEG-diamine and one chloro group in IR820). The reaction scheme is illustrated in 
Figure 3, and involves covalent attachment of the amine group in PEG-diamine to the 
cyclohexene in IR820 at the chloro-substituted position via nucleophilic substitution, 
with displacement of the chlorine atom and production of triethylamine hydrochloride. 
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After the reaction progressed to completion, the sample was concentrated and the residue 
was dissolved in 5 ml of water, followed by dialysis against water using a MWCO 3.5 
kDa for 24 hours. The nanoconjugates were freeze-dried using the Freezone system 
(Labconco, Free Zone Plus 6) for 24 hours, and stored in powder form at 4oC for further 
use. The reaction scheme was developed in consultation with Dr. Pradeep Kumar, from 
the Institute of Genomics and Integrative Biology in India. 
 
 
Figure 3. Reaction scheme and formulation of covalent IR820-PEG-diamine nanoconjugate (IRPDcov). 
2.3.3. Nanoconjugate characterization 
SEM pictures and zeta-potential measurements were obtained as described in section 
2.2.3. H-NMR measurements were performed with the assistance of Tereza Vokata, 
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graduate student at the FIU Chemistry Department. For H-NMR measurements, samples 
of IR820, PEG-diamine, and IRPDcov were dissolved in deuterated methanol. The 1H 
NMR spectra were recorded on a 400 MHz Avance Bruker NMR spectrometer using 240 
scans. Acquired data was processed and analyzed using MestReNova software. Chemical 
shifts were reported in parts per million (ppm) for 1H NMR on δ scale based on the 
MeOD solvent peak (δ = 3.31 ppm) as an internal standard. 
2.3.4. Dye content determination 
The IR820 content in the freeze-dried nanoconjugates was determined by dissolving a 
known amount of sample in DMSO, and following the procedures in section 2.2.4. 
2.3.5. Fluorescence stability studies 
We prepared samples of IR820 and IRPDcov in PBS buffer at concentrations in the linear 
range, and measured their baseline fluorescence emission profile after 785 nm excitation. 
The same procedures were followed as those described in section 2.2.5., except that 
fluorescence measurements were taken for up to 72 hours after sample preparation. 
2.3.6. Cytotoxicity with and without hyperthermia 
The cytotoxicity of four different treatments (IR820, IRPDcov, IR820 plus laser, and 
IRPDcov plus laser) was studied in cancer cell lines MES-SA, Dx5 and SKOV-3. The 
procedures followed were as described in section 2.2.8., with the use of IRPDcov in lieu 
of IR820-PDNCs. 
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2.3.7. Cellular imaging 
MES-SA, Dx5 and SKOV-3 cells were imaged after 4-hour exposure to either 5μM 
IR820 or equivalent free dye content of IR820PDcov, following the same procedures 
described in section 2.2.9.                                                                 
2.4. Materials and Methods for Specific Aim 4 
The methods used in the fulfillment of specific aim 4 are described and discussed in 
complete detail in chapter 6. Briefly, thirty-six healthy ND4 Swiss-Webster outbred mice, 
weighing between 25 and 30 grams, were purchased from Harlan (Indianapolis, IN), 
housed at the FIU Animal Care Facility under a 12-hour light/dark cycle and fed ad 
libitum. Mice were randomly assigned to one of twelve groups (n=3) based on optical 
agent (ICG, IR820, or IRPDcov), and time point of data collection after injection (15 
minutes, 30 minutes, 60 minutes, and 24 hours).  
 
For time groups in the range of minutes, mice were anesthetized with i.p. pentobarbital 
(100 mg/kg), shaved, placed supine on the imaging setup described in section 2.1.9., 
injected through the tail vein with their assigned agent, and imaged. At the predetermined 
time point, a blood sample was obtained under anesthesia by heart puncture into the 
ventricle, and the animal was then euthanized by removal of the heart.  
 
For mice in the 24-hour groups, each animal was anesthetized with 40 mg/kg of i.p. 
pentobarbital, injected with the assigned agent, and imaged. These mice were then 
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returned to their cage alive until the 24 hour time point. After 24 hours, they were 
anesthetized with pentobarbital (100 mg/kg) and imaged again under the same operating 
conditions. After imaging, a blood sample was obtained by heart puncture, and organs 
were carefully harvested for imaging and subsequent homogenization and dye extraction. 
Organ and plasma dye content were calculated from spectrofluorometric measurements 
of the samples using a previously created calibration curve of IR820 or ICG in DMSO at 
785 nm excitation. Specific pharmacokinetic analysis of plasma data and the choice of 
models for data fitting are both discussed in depth in chapter 6. 
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CHAPTER 3: IR820 CHARACTERIZATION AND                                    
THERANOSTIC APPLICATIONS 
The purpose of specific aim #1 was to determine the feasibility of using IR820 as a 
substitute for ICG in imaging and photothermotherapy applications, and to perform a 
general characterization of IR820 that can serve as a foundation for these applications. 
We performed an in vitro comparison of the two dyes with respect to their optical 
properties, thermal generation properties, stability profiles, and toxicity effects on cellular 
systems. Additionally, we directly compared in vivo imaging characteristics of ICG and 
IR820 in a rat model. This work has been published as a full journal article (Fernandez-
Fernandez et al., 2012). Permission has been obtained in writing from the journal editors 
to utilize content from this publication in the dissertation manuscript, and a copy of the 
aforementioned permission email is included in the appendices. 
 
Materials and methods for this specific aim were discussed in chapter 2. 
3.1. Physicochemical Characterization 
3.1.1. Absorbance studies 
Figure 4 shows the absorbance curves of IR820 and ICG in deionized water and 
methanol. In methanol, absorption peaks are located at 820 nm for IR820 and 779 nm for 
ICG. In water, the IR820 peak shifts to 691 nm, whereas peak absorption for ICG occurs 
at 784 nm. The observed hypsochromic shift in IR820 peak absorption in water versus 
methanol has been reported to exist in some heptamethine cyanine dyes, possibly as a 
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result of intramolecular charge transfer (ICT) or excited-state proton transfer (Peng et al., 
2005). Considering this property, we expect that the absorption peak for in vivo 
applications is likely to be located close to the 691 nm peak observed in water, and the 
higher wavelength methanol peak would only be relevant for in vitro applications in non-
physiological solvents. 
 
Figure 4. Absorbance spectra of IR820 and ICG in deionized water (solid) and methanol (dashed). 
3.1.2. Fluorescent spectrum characterization 
Figure 5 shows curves of fluorescence emission intensity versus wavelength for different 
ICG (5A) and IR820 (5B) concentrations in deionized water after excitation at 785 nm. 
Both dyes showed quenching for concentrations greater than 1.25 μg/mL, with similar 
linear ranges for both IR820 and ICG. This value is consistent with Saxena's reports of 
linearity for ICG aqueous solutions at concentrations below 2 μg/mL (Saxena et al., 
2003). Our results also show that, for a given concentration, IR820 has approximately ten 
times lower fluorescent yield than ICG after excitation at 785 nm.  
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A        B  
Figure 5. Fluorescence spectra after 785-nm excitation of aqueous solutions of (A) ICG and (B) IR820. 
 
Table 1 shows peak emission location for different concentrations of ICG and IR820. For 
ICG, the peak emission wavelength is dependent on concentration, and more 
concentrated samples show emission shifts toward longer wavelengths. In the case of 
IR820, peak location was not as dependent on concentration and remained between 822 
and 823 nm.  
 
 Emission Peak Location in nm, intensity  
Concentration (μg/mL) IR820 ICG 
2.5 823 nm, 9.86E4 807 nm, 1.19E6 
1.25 823 nm, 6.87E4 802 nm, 8.12E5 
0.625 822, 3.36E4 802 nm, 3.62E5 
0.3125 822, 1.09E4  800 nm, 1.35E5 
Table 1. Emission Peak Location for Aqueous Solutions of ICG and IR820. 
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Besides comparing the fluorescent behavior of IR820 and ICG after 785-nm excitation, 
we also studied the fluorescence properties of IR820 upon excitation at its 691-nm peak 
absorption in water. The profiles are shown in Figure 6 and are similar to those obtained 
for IR820 aqueous solutions after excitation at 785 nm. Again, quenching occurs above 
1.25 μg/mL, and peak emission is located at 822-823 nm. A slight increase in 
fluorescence emission of approximately 13-16% was observed for the emission spectrum 
after 691-nm excitation when compared with excitation at 785 nm. 
 
Figure 6. Fluorescence spectra after 691-nm excitation of aqueous solutions of IR820. 
 
The fluorescent emission profiles of IR820 show lower fluorescence intensities than ICG 
for equivalent concentrations. This was observed after 785-nm excitation as well as after 
691-nm excitation (at the optimal absorption peak of IR820 in water). The lower quantum 
yield after 785-nm excitation is expected based on the almost 100-nm difference with the 
absorption peak of IR820 in water. After 691-nm excitation, peak fluorescence intensities 
are higher than those observed after 785-nm excitation, but still lower than those of ICG. 
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Therefore, there must be a structural factor that contributes to this behavior. Most likely, 
the observed phenomenon is related to the intrinsic low quantum yield of the 
chlorohexene ring (Shimoda et al., 1979), as well as to the internal heavy atom effect by 
which a chlorine atom within the structure typically results in decreased quantum yields 
and fluorescent lifetimes (Mac et al., 2003). 
 
An advantage of IR820 fluorescence emission is that peak location for fluorescent 
emission has little dependence on concentration, in contrast with ICG where we observe 
more variability and a shift towards lower wavelengths with decreasing concentration. 
The predictability of peak location for IR820 could facilitate the design of imaging 
systems targeting IR820 emission wavelengths and diminish some of the challenges that 
may arise with concentration-dependent peaks in ICG.  
 
3.1.3. Effects of temperature and light on stability in aqueous solution 
Aqueous solutions of IR820 and ICG were exposed to different temperatures (4°C, room 
temperature, and 42°C) and light conditions (dark room, covered with foil, or direct 
exposure to light). The degradation profiles of IR820 and ICG solutions, as shown in 
Figure 7 (different temperatures) and Figure 8 (different light levels), follow pseudo-first 
order kinetics with exponential decay. Covering the samples with foil was comparable, in 
terms of delaying degradation, to keeping them in a dark room. As expected based on the 
presence of the mesochlorohexene ring that confers rigidity to the molecule, IR820 
demonstrated higher stability than ICG in aqueous solution under all temperature and 
light conditions, with degradation half-times approximately double those of ICG for a 
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given experimental condition. This is illustrated in Table 2. The degradation half-times 
for ICG in this study were consistent with those reported by other groups for this dye 
(Saxena et al., 2003). Direct light exposure and high temperatures resulted in fast 
degradation for both dyes and loss of smooth spectral features by day 4.  
        
Figure 7. Effect of temperature on degradation of aqueous solutions of IR820 and ICG. Solid lines 
correspond to IR820 and dotted lines correspond to ICG. Error bars are ± SD. 
 
 
Figure 8. Effect of light on degradation of aqueous solutions of IR820 and ICG. Solid lines correspond to 
IR820 and dotted lines correspond to ICG. Error bars are ± SD. 
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IR820 ICG 
Experimental 
conditions 
kobs 
 (hour -1) 
t 1/2 
(hours) 
R2 
kobs 
(hour -1) 
t 1/2 
(hours) 
R2 
Light, 22°C 0.028 24.75 0.994 0.051 13.59 0.987 
Dark, 22°C 0.020 34.65 0.992 0.042 16.50 0.992 
Dark, 4°C 0.019 36.47 0.981 0.036 19.25 0.995 
Dark, 42°C 0.035 19.80 0.984 0.064 10.83 0.989 
Table 2. Stability characterization of aqueous solutions of IR820 and ICG following a pseudo-first order 
kinetics model. 
 
Our results showing that IR820 is more stable in aqueous solution than ICG are 
consistent with other literature reports that describe structure-function relationships for 
fluorescent cyanine dyes (Lee et al., 2008).  Lee’s group reported that increased rigidity 
of the molecular structure of a dye results in enhanced stabilization of the molecule. 
Interestingly, temperature seemed to not be as important as light exposure in determining 
the degradation behavior of IR820 solutions. We did not observe any enhancement in 
stability when IR820 solutions were kept at 4°C in the dark versus when samples were 
stored at room temperature in the dark; however, there was a difference between the two 
conditions for ICG. Therefore, light exposure seems to be the most important influencing 
factor in degradation mechanisms of IR820, rather than temperature, unless temperatures 
are as extreme as those of a water bath (42°C). At such elevated temperatures, heat 
collisions increase significantly and the molecules tend to aggregate closer together, 
leading to increased degradation of the fluorescence properties. 
49 
 
3.1.4. Stability in different solvents under constant light and temperature conditions 
ICG and IR820 were both stable in DMSO and methanol over a period of 4 days, with no 
significant decrease in fluorescence intensity when comparing samples measured on day 
1 versus samples measured on day 4 (p>0.05, paired t-test). Thus, both dyes showed 
excellent stability in methanol and DMSO.  
 
3.1.5. Hyperthermia properties 
Figure 9 illustrates changes in temperature during 180 seconds of 808-nm laser exposure 
for IR820 (Figure 9A) and ICG (Figure 9B), with a starting temperature of 37°C. For 
equivalent concentrations, the peak temperature increase for IR820 was significantly 
smaller than the increase observed in ICG (4-9% difference in peak temperature, p<0.05 
for comparisons between equivalent dye concentrations).  
A B  
Figure 9. Heat generation profile of wells containing IR820 (A) or ICG (B) when irradiated with NIR laser 
for a total of 3 minutes. 
 
Although IR820 did not generate peak temperatures as high as those of ICG after three-
minute laser exposure, at 5 μM and 10 μM the IR820 temperatures were still within the 
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hyperthermia range of 40-43°C that is able to selectively impact tumor cell growth. 
Tumor cells are sensitive to temperatures in this range, whereas the growth of normal 
cells is not affected until temperatures reach higher levels (Baronzio et al., 2006).  
Although a higher concentration of IR820 will be needed to attain the same temperature 
as ICG in hyperthermia applications, it is still feasible to achieve temperatures in the 
desirable 40-43°C range with as little as 5 μM IR820. 
 
Samples from the 5 μM stock solutions, kept at 4°C in the dark, were also tested 3 days 
and 6 days after the initial experiment to investigate the stability of heat generation 
properties after the dye is in solution. The hyperthermia properties of both dye solutions 
when irradiated with 808-nm light are stable over a period of 3 days, with no significant 
changes in peak temperature generation in terms of percent of original peak temperature 
recorded on the day of preparation. After 6 days, there is a significant decrease in peak 
temperature for both dyes (p<0.05 compared to the initial peak). Even though the 
decrease is significant with respect to the initial time point, both dyes still reach peak 
temperatures higher than 41°C after 6 days. The stability of hyperthermia generation 
presents a stark contrast to the rapid decay of fluorescence properties in aqueous solution, 
indicating that non-radiative processes such as heat generation show a different behavior 
over time compared to radiative processes such as fluorescence.  
3.2. Cellular Experiments 
Cellular experiments included cytotoxicity experiments with and without hyperthermia, 
as well as fluorescent cell imaging. 
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3.2.1. Cytotoxicity experiments 
Figures 10, 11, and 12 show the results of cytotoxicity experiments in SKOV-3, Dx5, and 
MES-SA cells, respectively.  
 
Figure 10. IR820 and ICG cytotoxicity and hyperthermia effects in SKOV-3 cells. * = significant 
difference (p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of 
dye without laser. 
 
Figure 11. IR820 and ICG cytotoxicity and hyperthermia effects in Dx5 cells. * = significant difference 
(p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of dye 
without laser. 
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Figure 12. IR820 and ICG cytotoxicity and hyperthermia effects in MES-SA cells. * = significant 
difference (p<0.05) versus control group; ** = significant difference (p<0.05) versus same concentration of 
dye without laser. 
 
Net cell growth was normalized to a control group that was not exposed to either dye or 
laser. NIR-laser treatment by itself without addition of IR820 or ICG did not affect cell 
viability for any of the cell lines. In the presence of ICG or IR820, the cytotoxicity 
profiles of SKOV-3 (Figure 10) and Dx5 (Figure 11) were very similar. In these two cell 
lines, concentrations up to 10 µM IR820 or ICG without laser treatment did not cause 
significant decreases in cell viability when compared to the control group that received 
no dye and no laser treatment. In MES-SA cells (Figure 12), there was significant (p< 
0.05) cell growth inhibition upon exposure to 5 µM or 10 µM IR820 dye without laser 
treatment. This is likely due to the fact that MES-SA cells are more sensitive to 
environmental stressors than the other two cell lines, which are resistant to chemotherapy. 
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When compared to the group that received laser treatment only, laser treatment of cell 
lines exposed to IR820 or ICG caused significant (p<0.05) cell growth inhibition at 5 µM 
dye concentration, and significant cell growth inhibition or cell killing at 10 µM, 
indicating that both dyes can cause hyperthermia that impacts cell viability. Additionally, 
for all cell lines, when comparing the effects of a given dye concentration with and 
without NIR-laser treatment, cell proliferation was significantly lower in the NIR laser 
treatment group versus the dye-only group for both dyes at 5 and 10 µM. 
Thus, our cytotoxicity data shows that both IR820 and ICG hyperthermia cause 
significant cancer cell growth inhibition at 5 µM, and significant cell growth inhibition or 
cell killing at 10 µM. There is no statistical difference in the effect on net cell growth 
between IR820 and ICG hyperthermia for a given concentration, indicating that IR820 is 
a good substitute for ICG in therapeutic applications of hyperthermia.  
3.2.2. In vitro cell imaging 
Figure 13 shows images of MES-SA, SKOV-3, and Dx5 cells after 30-minute incubation 
with IR820 or ICG, at image exposure times well under the 20,000 ms threshold for 
cellular autofluorescence. The level of fluorescent brightness for both dyes allows for 
sensitive cell imaging of cancer cell lines, and IR820 images are very similar to those 
obtained with ICG. Similar dye distributions were observed for all cell lines in the 
fluorescence microscope images. Both dyes resulted in widespread cytoplasmic 
fluorescence along with a localized perinuclear signal. The cell images show some areas 
in the cytoplasm where the fluorescent intensity seems to be higher for both dyes. This 
may be due to intravesicle storage of the dyes (Quarta et al., 2009), or binding to 
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cytoplasmic proteins such as ligandin (Kaplowitz et al., 1975). Other researchers have 
reported that the amphiphilic characteristics of ICG cause specific interactions with the 
phospholipid bilayer (Desmettre et al., 2000), and the structural similarity of IR820 may 
result in similar interactions.  
 
Image intensities for cells exposed to IR820 and ICG were comparable, despite the fact 
that our spectrofluorometer studies show smaller emission intensities for IR820 compared 
to ICG at equivalent concentrations. An additional consideration is that, based on its 
better stability in aqueous solution, it is possible that IR820 could show an advantage 
over ICG in long incubation periods and longer imaging windows.  
 
Figure 13. Cellular imaging after incubation with IR820 or ICG. A and D, SKOV-3 were incubated for 30 
minutes with 10 μM IR820 and ICG respectively. B and E, Dx5 were incubated for 30 minutes with 10 μM 
IR820 and ICG respectively. C and F, MES-SA were incubated for 30 minutes with 10 μM IR820 and ICG 
respectively. λex = 775 nm and λem = 845 nm. Objective magnification, 60X. 
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3.3. In vivo Imaging Studies 
Figure 14 shows sample abdominal images of a rat 40 minutes after i.v. injection with 
IR820 (14A) or ICG (14B) and excitation with a 60 mA 785-nm laser module. Both dyes 
accumulated primarily in the liver, which is consistent with literature reports for the 
biodistribution of ICG (Jiao et al., 2000). As expected from the lower fluorescence 
intensities observed during in vitro optical experiments, the intensity of the IR820 image 
following injection was lower than for the ICG image at equivalent molar dosages. An 
additional reason could be that our imaging system was optimized for ICG imaging with 
excitation at 785 nm. It is important to consider, however, that in vitro profiles cannot 
fully predict behavior in an in vivo environment, where protein and surface binding could 
have a large effect on fluorescent properties (Mordon et al., 1998). Interestingly, despite 
the initial larger signal for ICG, imaging the same animal after 24 hours resulted in 
normalized intensities that were higher for IR820 (14C) than for ICG (14D).  
 
Figure 14. Rat abdomen images 40 minutes after i.v. injection with IR820 (A) or ICG (B), and 24 hours 
after injection with IR820 (C) or ICG (D). Image ratios indicate signal intensity normalized to area in μm2. 
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Area normalized image intensities (n=3) for IR820 and ICG are shown in Table 3. The 
quantitative measurements confirm that the abdominal ICG signal was significantly 
stronger than the abdominal IR820 signal immediately after injection (p<0.05), but the 
opposite was true 24 hours later.  
 
 Image intensity per area,  R (1/μm2) 
Image at 60 mA laser current  ICG (n =3)  IR820 (n=3)  
Abdomen, 40 minutes after injection  11.49 ± 2.49 (*) 4.74 ± 0.52 
Abdomen, 24 hours after injection  1.86 ± 0.52 5.79 ± 0.86 (*) 
Liver, 24 hours after injection 7.01 ± 4.01 14.87 ± 2.90 (*) 
Kidneys, 24 hours after injection 2.18 ± 0.48 9.52 ± 3.04 (*) 
Lungs, 24 hours after injection  1.06 ± 1.84 4.10 ± 0.81 (*) 
Table 3. Image intensity per area in μm2 for different locations and time points after IR820 and ICG 
administration. Values are average ± standard deviation. (*) = significant difference between dye signals, p 
<0.05, for a given location and time point. 
 
 
Also, when the organs were extracted and imaged after 24 hours, as shown in Figure 15, 
we can see that IR820 was present in liver, lungs and kidneys, whereas the ICG signal 
was mostly limited to the liver. In Table 3, this qualitative observation is confirmed by 
the area-normalized intensities, which are significantly higher (p<0.05) for IR820 
compared to ICG in liver, lungs, and kidneys 24 hours after the animal was injected with 
the dye.  
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Figure 15. Rat liver, lung, and kidney images 24 hours after injection with IR820 or ICG.   Ratios indicate 
signal intensity normalized to area in μm2. 
 
Table 4 shows the quantitative organ dye content data obtained after homogenization and 
DMSO extraction.  
 Organ dye content (μg/g tissue) 
 ICG (n =3)  IR820 (n=3)  
Liver  0.014 ± 0.009 0.819 ± 0.290 (*) 
Lungs  0.021± 0.026 0.066± 0.018  
Kidneys 0.005 ± 0.002 0.166 ± 0.020 (*) 
Table 4. Organ dye content (μg/g tissue) 24 hours after injection.  Values shown are average ± standard 
deviation, and (*) = significant difference, p <0.05. 
In accordance with the images shown above and the area-normalized intensities, organ 
content of IR820 (μg/g tissue) was significantly higher (p<0.05) than ICG in liver and 
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kidneys 24 hours post injection. For the lungs, IR820 content was higher than ICG 
content, but the difference did not reach statistical significance (p = 0.066).  
 
Our rat organ studies showed that both dyes are processed primarily in the liver, but 
IR820 seems to significantly accumulate in the kidneys as well. Interestingly, when 
images were taken from the chest area after 24 hours, there was a signal from IR820 but 
not from ICG, indicating that IR820 may localize to the lungs to a larger extent than ICG. 
The lung image data is consistent with this observation, and shows a significant 
difference in intensity ratios for IR820 and ICG in the lungs (p<0.05). However, the 
difference in lung dye content did not reach statistical significance (p = 0.066). In one of 
the ICG experiments, small “hot spots” were observed in the lungs 24 hours after 
injection, which may have been due to ICG aggregation in the blood resulting in lung 
accumulation. There was no ICG detected in the lungs of the other two rats 24 hours after 
injection. On the other hand, the lack of statistical significant could also be due to simple 
individual variability between subjects, which is also the source of other differences 
between fluorescent images.   
 
In summary, after 24 hours we observed a stronger signal in the intact animal for IR820 
compared to ICG, and both the organ images and quantitative dye content analysis show 
that IR820 is present in higher amounts than ICG in liver, kidneys, and lungs.  This may 
result in an advantage over ICG for imaging studies by providing longer image collection 
windows, and is consistent with data reported by Prajapati et al (Prajapati et al., 2009). 
This group observed increases in IR820 fluorescence upon binding to serum albumin, and 
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they estimated that IR820 would have an approximate clearance half-life of 35 hours in 
mice based on the half-life of albumin and on images collected over a span of 8 days in 
mice. They did not take plasma samples or perform pharmacokinetic analysis upon i.v. 
injection. As we will discuss in chapter 6, our pharmacokinetic experiments in mice 
confirmed the increased plasma half-life of IR820 when compared to ICG. Our studies in 
mice support Prajapati’s estimates, as well as the results discussed in the current chapter 
for the rat model. 
 
3.4. Summary 
IR820 could be an alternative to ICG in imaging and hyperthermia applications based on 
its enhanced stability, feasibility of use for in vitro and in vivo imaging, and hyperthermia 
generation properties. IR820 may be used under circumstances where longer image 
collection times or more predictable peak locations are desirable, and even though it does 
not elevate temperature as sharply as ICG for equimolar concentrations, IR820 is able to 
generate a cytotoxic environment upon laser exposure than can inhibit the growth of 
cancer cells, or even result in cell killing. The optimal dye concentration for dual in vivo 
imaging and hyperthermia treatment would depend on dye toxicity, hyperthermia tumor 
killing effect, plasma clearance and instrument sensitivity. Additional issues that must be 
considered include in vivo attenuation, as well as accumulation at desired target sites such 
as tumor areas. Potential approaches to solve these problems include targeted 
formulations of the dye, nanoformulations which can take advantage of the EPR effect, 
and endoscopic or orthoscopic delivery of light for imaging and inducing hyperthermia. 
The presence of the chlorohexene ring makes IR820 more amenable to conjugation 
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chemistry compared to ICG, and provides opportunities for preparation of conjugate 
formulations of the dye. Since aggregation of dye molecules is an important mechanism 
for degradation of cyanine dyes, covalent conjugation of IR820 to other moieties could 
result in formulations with enhanced stability.  Versatility in selecting the conjugation 
moiety also opens opportunities for imparting different functionality or properties to the 
molecule. The development of specific nanoformulations of IR820 to enhance target site 
accumulation, exposure, and toxicity to cancer cells while providing longer windows for 
imaging and therapy may have significant potential as a theranostic approach to cancer 
management.  
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CHAPTER 4: PREPARATION AND CHARACTERIZATION OF IONIC IR820-
PEG DIAMINE NANOCONJUGATES (IR820-PDNCs)                                            
Clinical translation of NIR-imaging and hyperthermia approaches in cancer must 
overcome the challenges presented by free dye formulations in terms of plasma 
circulation times and non-specific biodistribution. Nanotechnology provides some 
opportunities to improve in vivo stability and target delivery. Intrinsic characteristics of 
nanoformulations such as size, surface moieties, and charge can be customized in order to 
modify their interactions with circulating proteins and cellular membranes. Additionally, 
due to their size, nanosize agents are less susceptible to reticuloendothelial system 
clearance, and in general have improved in vivo penetration into tissues and cells (Brigger 
et al., 2002; Xu et al., 2006). The enhanced permeability and retention (EPR) effect also 
acts as a passive targeting mechanism allowing nanoformulations to accumulate 
preferentially at tumor sites. Immune responses to circulating foreign objects can be 
reduced by coating nanoformulations with polyethylene glycol (PEG), thus resulting in 
improved plasma circulation times (Harris et al., 2001). PEG can also be utilized as a 
linker for antibody conjugation, which opens the possibility of actively targeted therapy 
to further reduce uptake in non-tumor areas and increase the efficacy and safety of these 
nanoformulations.  
 
Specific aim #2 focused on the development and characterization of ionic IR820-PEG-
diamine nanoplexes (IR820-PDNCs), and on researching their potential use in localized 
hyperthermia and imaging. The size and surface morphology of these nanoplexes were 
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characterized by SEM, and the optical properties in solution were studied using 
spectrofluorometry and spectrophotometry. We explored possible applications through in 
vitro experiments with three different human cancer cell lines (MES-SA, Dx5, and 
SKOV-3) to investigate the feasibility of using the nanoplexes as imaging agents, and to 
determine whether this formulation retained the ability to induce hyperthermic cell 
killing.  
 
This work has been published as a full journal article (Manchanda et al., 2012). 
Permission has been obtained in writing from the journal editors to utilize images and 
content from this publication in the dissertation manuscript, and a copy of the 
aforementioned permission email is included in the appendices. 
 
Materials and methods for this specific aim were discussed in chapter 2. 
4.1. Characterization of IR820-PDNCs 
Nanoplexes of PEG-diamine and IR820 were formed by electrostatic interactions 
between oppositely charged groups in PEG-diamine and IR820. Since IR820 is a 
monosodium salt, 50% of the molecules will remain in acid form at physiological pH. 
IR820-PDNCs size and morphology were characterized using SEM, which showed 
nanoplexes of approximately 50-100 nm diameter (Figure 16). The zeta potential of 
IR820-PDNCs was 2.0±0.9 mV. PEG-diamine charges are neutralized during 
formulation, so the remaining charge arises primarily from the sodium salt charge of 
IR820 in its acid form and from nitrogen moieties. These charges make the nanoplexes 
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dispersible in aqueous solution, with PEG-mediated steric repulsion also playing a role in 
enhancing water dispersibility by preventing complex aggregation. 
 
Figure 16. SEM image of IR820-PDNCs. 
 
Particle yield was 25% for a 6k-PEG diamine formulation. IR820-PDNCs fluorescent dye 
content was determined by spectrofluorometry to be approximately 0.125 mg IR820/mg 
IR820-PDNCs. Samples of IR820-PDNCs were also analyzed by FTIR, ν = 1395 cm− 1 
(C-S stretching), 1055 cm− 1 (C-O-C stretching), 894 cm− 1 (C-Cl stretching on 
conjugated dienes). These characteristic peaks indicate the participation of PEG-diamine 
as well as IR820 in the complex driven by electrostatic interactions. Although ionic 
formulations may not be as stable as a covalent linkage, ionic formulations have been 
used to provide improved delivery of therapeutic agents to cells (Nimesh et al., 2006), 
indicating that they have potential for clinical translation. Molecules coupled by 
electrostatic interactions typically maintain their native structure and activity, thus 
preserving their biological function (Wu et al., 2011). Ionic formulations may also 
present physiological advantages in terms of enhanced ion exchange processes or 
enhanced degradation after cellular internalization (Nimesh et al., 2006). Additionally, 
66 
 
many ionic formulations can be readily converted into covalent interactions through the 
use of coupling agents or linkers. The study of IR820-PDNCs can provide valuable 
information as to whether IR820 remains optically and thermally active when in close 
proximity to other molecules, and to determine whether molecular interactions impact its 
ability to function as a theranostic agent. 
4.1.1. Absorbance studies 
The UV-visible spectra of IR820, PEG-diamine and IR820-PDNCs are shown in Figure 
17. Concentrations of PEG-diamine and IR820 were chosen based on molar ratios used in 
the formulation of the nanocomplexes, and IR820-PDNCs concentration was chosen to 
approximately match the concentration of the IR820 solution given the previously 
estimated dye content (0.125 mg IR820/mg IR820-PDNCs).  
 
Figure 17. Absorption spectra of IR820 (solid black), IR820-PDNCs (dashed black) and PEG-diamine 
(gray) in deionized water. 
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IR820-PDNCs displayed three characteristic absorption peaks located at 690, 785, and 
844 nm, between 0.677 and 0.906 A.U. at 6.25 μg/mL dye concentration. There were no 
peaks above 0.01 A.U. between 200 and 900 nm for PEG-diamine at 24 μg/mL. The free 
dye spectrum showed a single peak at 688 nm with almost the same absorption intensity 
as the IR820-PDNCs solution. Therefore, the absorption spectra confirmed the validity of 
the spectrofluorometric dye content determination, based on the close match for the 688-
690 nm peak. The other two peaks are unique to the nanoplex formulation and reflect 
additional vibrational transitions, which may stem from interactions between functional 
groups within the conjugate lattice, or from intermolecular hydrogen bonding (Mansoori 
et al., 2010)  
4.1.2. Fluorescence properties of IR820-PDNCs 
Excitation of IR820-PDNCs at 690 nm or 844 nm did not produce a significant 
fluorescence emission. There is probably translation of excitation energy into heat or 
vibrational energy at these wavelengths. After 785-nm excitation, the nanocomplexes 
demonstrated fluorescent emission. A representative fluorescence emission spectrum of 
IR820-PDNCs after 785-nm excitation is shown in Figure 18 along with the 
corresponding profile for IR820 at comparable dye content. The shape of the two profiles 
is quite similar, although the emission peak intensity is about 15% lower for IR820-
PDNCs than IR820. The slight reduction in fluorescence intensity may be a result of 
interactions with the buffer solvent, changes in electronic excitation energy transfer 
mechanisms after the dye becomes part of the nanoplex lattice, absorption of 
fluorescence emission at secondary absorption peaks, or perhaps a combination thereof.   
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Figure 18. Fluorescence spectra of IR820 and IR820-PDNCs in phosphate buffered saline. 
4.1.3. Fluorescence stability studies 
IR820-PDNCs and IR820 solutions in buffer were measured 4 hours after preparation to 
determine the percent remaining fluorescent intensity compared to baseline. IR820-
PDNCs showed a significantly (p<0.05) higher percent remaining intensity (68.9%) 
compared to IR820 (58.9%) after 4 hours. This indicates that the ionic interactions within 
the nanoplex lattice conferred added stability and protected the dye from degradation.  
4.2. Cell Imaging Studies 
Figure 19 shows fluorescence microscopy images of Dx5, SKOV-3 and MES-SA cell 
lines after 2.5 hours incubation at 5 μM concentration of IR820 and IR820-PDNCs at 
equivalent dye content. This concentration was chosen based on our previous cellular 
studies with IR820 (Fernandez-Fernandez et al., 2012). In all three cell lines, intense 
fluorescence was observed inside the cells after 2.5 hour incubation with IR820 or IR820-
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PDNCs, indicating that both the free dye and the nanoplexes were capable of entering the 
cells. However, the images taken after IR820-PDNCs incubation showed higher 
normalized intensity ratios than those taken after incubation with equivalent 
concentrations of IR820, especially in SKOV-3 and Dx5. Normalized intensity ratios for 
IR820-PDNCs were 2.1 times larger than for IR820 in SKOV-3 (R = 2.6 for IR820 
versus R= 5.6 for IR820-PDNCs) and 1.7 times larger in Dx5 (R = 3.8 for IR820 versus 
R = 6.5 for IR820-PDNCs). In MES-SA, the ratio showed a moderate increase (R= 5.7 
for IR820 versus R = 6.9 for IR820-PDNCs).  
 
Figure 19. Cellular imaging of Dx5 (A, B), SKOV-3 (C,D) and MES-SA cells (E,F) after 2.5 hour 
incubation with 5 μM dye content of IR820-PDNCs (top) or IR820 (bottom); 60x, exposure time 4000 ms. 
It is possible that the presence of PEG resulted in enhanced cell membrane interaction 
and increased internalization compared to free dye, as PEG has been reported to mediate 
solubilization of nanoformulations in the lipid bilayer. This results in enhanced solubility 
in cell membranes and increased non-specific cellular uptake (Yamazaki et al., 1990; 
Zhang et al., 2002). High concentrations of PEG in close proximity to cellular 
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membranes create osmotic stress and osmoelastic coupling, which result in membrane 
instability, enhanced leakiness and PEG-induced fusion vesicles without the need for 
direct contact with PEG (Yamazaki et al., 1990). It is possible that exposure of cells to 
IR820-PDNCs creates such an effect based on the osmotic effects of PEG, even if some 
of the charge was neutralized during nanocomplex formation.  
4.3. Cytotoxicity Studies without Hyperthermia 
SKOV-3, Dx5 and MES-SA cells were chosen to study the cytotoxic effect of IR820 and 
IR820-PDNCs on tumor cells using the SRB assay. The cells were incubated with 
increasing concentrations of IR820 or IR820-PDNCs for 24 hours up to a maximum dose 
of 5 μM IR820 content, in order to compare the toxicity profile of the nanoplexes and the 
free dye. Figure 20 shows net cell growth following incubation with IR820 or IR820-
PDNCs for SKOV-3, Dx5, and MES-SA.  
 
There was no significant difference in net cell growth between the IR820 group and the 
IR820-PDNCs group for equivalent dye concentrations for any cell line. In SKOV-3 and 
Dx5, there was also no significant cytotoxicity for any concentration of IR820 or IR820-
PDNCs compared to the control group which was not exposed to dye. On the other hand, 
MES-SA cells showed significant (p<0.05) 17-25% cell growth inhibition at 5 μM 
concentrations of either treatment, consistent with our prior observations discussed in 
chapter 3, and again likely due to the fact that MES-SA cells are more sensitive to 
environmental stressors than the other two cell lines, which are resistant to chemotherapy.   
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Figure 20. Cytotoxicity of IR820-PDNCs or IR820 in cancer cell lines. Bars represent net cell growth after 
24-hour exposure, n = 3 experiments, 4 wells per treatment. * = significant difference (p<0.05) versus 
control (0 μM) group. 
 
We also performed studies with exposure to (1) dye content of 25 μM, which resulted in 
> 50% growth inhibition in all three cell lines for both IR820 and IR820-PDNCs; and (2) 
PEG-diamine at 50 μM concentration, which is 20 times higher than the concentration of 
PEG-diamine in nanoplexes containing 5 μM of IR820, and showed no toxicity in any of 
the cell lines. The overall cytotoxicity results indicated that IR820-PDNCs have a toxicity 
profile comparable to the free dye, and they can be safely used up to at least 5 μM, which 
is within the applicable range for biological studies such as imaging. 
4.4. Hyperthermia Studies  
Our previous work has shown the ability of IR820 to induce hyperthermic cell growth 
inhibition and cell killing (Fernandez-Fernandez et al., 2012). We tested IR820-PDNCs 
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to determine whether the dye within the nanoplex still retained the ability to generate heat 
when exposed to an 808-nm NIR laser. At a laser fluence rate of 8 W/cm2, a solution of 
0.034 mg/ml IR820-PDNCs (containing 5 μM IR820) caused an increase in temperature 
from 37°C to 42.5°C after 3 minutes of exposure. This temperature is within the range 
used for localized hyperthermia aiming to affect tumor cells while sparing healthy cells.. 
Research has shown that moderate hyperthermia (41-43 °C) is able to cause significant 
tumor cell growth inhibition but does not greatly affect healthy cells. The reason for this 
differential behavior upon hyperthermia exposure is that cancer cells have mechanisms 
that inhibit oxidative metabolism which are specifically activated by temperatures in this 
range (Cavaliere et al., 1967; Luk et al., 1980; Tang et al., 2009). We also tested PEG-
diamine by itself, which did not result in significant changes in temperature after 3-
minute laser exposure compared to wells containing medium only. Therefore, 
hyperthermia generation stems from the IR820 portion of the nanoplexes.  
 
Nanoplex-induced hyperthermia may have the potential to enhance toxicity compared to 
free dye based on factors unique to the nanoformulation such as size, charge, enhanced 
interaction with cell membranes, or overall increased internalization of the nanoplexes. In 
order to study the effects of nanoplex hyperthermia on cellular systems, we tested MES-
SA, Dx5 and SKOV-3 cell proliferation with and without laser irradiation. The results are 
shown in Figure 21. All groups were normalized to the control group not exposed to dye 
or laser. As discussed in chapter 3, there was no significant effect of laser exposure on 
cell growth without exposure to dye. Cell growth was significantly inhibited in all three 
cell lines by both IR820 and IR820-PDNCs when exposed to laser. In MES-SA and Dx5 
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cell lines, IR820-PDNCs hyperthermia resulted in significantly higher cytotoxicity (p< 
0.05) compared to IR820. In SKOV-3 cells, IR820-PDNCs hyperthermia produced 
higher cytotoxicity than free dye, but not enough to reach statistical significance. 
 
Figure 21. Cytotoxicity of hyperthermia treatment with 5 μM dye content of IR820 or IR820-PDNCs, n = 3 
experiments, 4 wells/experiment. All groups are normalized to the control group not exposed to dye or 
laser. There was no significant effect of laser exposure per se without IR820-PDNCs or IR820, and there 
was no significant effect of PEG-diamine exposed to laser.  * = significant difference (p<0.05) versus non-
laser group, **= significant difference (p<0.05) between laser groups.   
 
Based on the cell imaging results displayed in Figure 19, IR820-PDNCs were 
internalized more readily by cells than the free dye. This is consistent with the increased 
cytotoxicity effect of the hyperthermia treatment that can be observed in Figure 21. 
Enhanced internalization would result in improved ability to cause damage to cells by 
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heat generation compared to free dye. It is interesting to note that the enhanced cytotoxic 
effect reached statistical significance in MES-SA and Dx5 cell lines, but not in SKOV-3. 
This could be due to inherent insensitivity to hyperthermia in SKOV-3. These cells have 
a p53 deletion gene mutation that affects their response to different cytotoxic agents. It is 
possible that the mutation may also influence apoptotic response to hyperthermia events, 
although this issue is controversial.  
 
Some studies suggest that hyperthermia-induced apoptosis is independent of p53 
mutations (Fukami et al., 2004; Sturm et al., 2006). Tang et al found that simultaneous 
use of ICG hyperthermia and doxorubicin chemotherapy in SKOV-3 resulted in increased 
cell growth inhibition compared to chemotherapy alone or hyperthermia alone. This 
would seem to indicate that these cells can still be affected by hyperthermia despite the 
p53 mutation (Tang et al, 2009). However, other groups have reported that the process of 
apoptosis after hyperthermia can depend on p53 expression and may occur in both a p53-
dependent and -independent manner (Goto et al., 1999; Ohnishi et al., 2008; Seo et al., 
1999; Takahashi et al., 2003). Further studies are needed to clarify the effect of p53 gene 
deletion on the response to localized NIR-dye mediated hyperthermia. 
 
Given that PEG diamine has the potential to generate peroxide radicals upon light 
exposure, it may create increased oxidative stress in cells exposed to a laser. In order to 
explore this possibility, we also tested a PEG-diamine only group. MES-SA, Dx5, and 
SKOV-3 were exposed to 2.5 µM PEG-diamine (based on the molar formulation ratio of 
1:2 PEG-diamine to IR820) and received laser treatment as previously described. Our 
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results showed that there were no significant differences in cell growth (p>0.05) for the 
PEG plus laser group compared to either the control group that was not exposed to PEG-
diamine, or to the group that received PEG-diamine without laser treatment.  Therefore, 
PEG-diamine by itself did not cause oxidative stress levels able to significantly affect cell 
growth after laser exposure.  
 
Our results showed an enhanced effect of IR820-PDNCs hyperthermia in Dx5 and MES-
SA cells. Increases in cell internalization may play a role in explaining this difference, 
but the co-localization of PEG-diamine and IR820 could also be an important factor to 
consider. Although PEG-diamine free radical generation is not sufficient to significantly 
affect cell growth, research has shown that the presence of free radical generators can 
enhance the effect of hyperthermia, because some mechanisms of cell death in 
hyperthermia are tied to oxidative stress responses (Li et al., 2001; Skibba et al., 1997; 
Wada et al., 2005; Yuki et al., 2003).  
 
In the case of IR820-PDNCs, which contain both IR820 and PEG-diamine, it is possible 
that simultaneous increased temperature (from IR820 hyperthermia) and free radical 
generation (from PEG-diamine laser exposure) could have resulted in enhanced 
cytotoxicity compared to free dye hyperthermia for Dx5 and MES-SA cells, even if free 
radical generation from PEG-diamine in isolation does not have an effect. This could 
provide an advantage to the nanoplex formulation with respect to individual therapies by 
achieving codelivery and combined action of its components.  
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4.5. Summary 
Under this specific aim, we successfully prepared ionic nanocomplexes of IR820 and 
PEG-diamine (IR820-PDNCs), characterized their optical properties and investigated 
their cytotoxicity with and without laser exposure in cancer cell lines MES-SA, SKOV-3 
and Dx5. The nanoplexes were able to generate a cytotoxic hyperthermia effect, as well 
as to emit a fluorescence signal that can be used for imaging. This formulation can 
potentially provide an advantage over the use of free agents by enhancing cell uptake, 
allowing simultaneous co-localization of imaging and therapy, and accentuating the 
cytotoxic effect of hyperthermia. Modifications in nanoplex formulation to create 
covalent conjugates could improve on the stability of the lattice and result in nanosize 
conjugates that may be used in in vivo applications.  
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CHAPTER 5: PREPARATION AND CHARACTERIZATION OF COVALENT 
IR820-PEG DIAMINE NANOCONJUGATES (IRPDcov) 
Specific aim #3 focused on the development and characterization of covalent IR820-
PEG-diamine nanoconjugates (IRPDcov), and on researching their potential use in 
localized hyperthermia and imaging. The size and surface morphology of these 
nanoconjugates were characterized by SEM, conjugation was confirmed by H-NMR, and 
the optical properties in solution were studied using spectrofluorometry and 
spectrophotometry. We explored possible applications through in vitro experiments with 
three different human cancer cell lines (MES-SA, Dx5, and SKOV-3) to investigate the 
feasibility of using the nanoconjugates as imaging agents, and to determine whether this 
formulation retained the ability to induce hyperthermic cell killing. Promising results led 
to in vivo testing, which is discussed under chapter 6 as specific aim #4. 
 
The work described in chapters 5 and 6 is currently a manuscript in preparation for 
submission to the Journal of Biomedical Optics. 
 
Materials and methods for specific aim # 3 were discussed in chapter 2. 
5.1. Characterization of IRPDcov 
Covalent nanoconjugates of PEG-diamine and IR820 were prepared by mixing IR820 
and 6kDa PEG-diamine (2:1 ratio) in methanol and refluxing for 4 hours in the presence 
of triethylamine (2 eq.), with displacement of the chlorine atom by nucleophilic 
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substitution and production of triethylamine hydrochloride. Then, the solvent was 
removed, the residue dissolved in water, dialyzed against water, freeze-dried, and stored 
in powder form at 4ºC for further use. IRPDcov size and morphology were characterized 
using SEM, which showed nearly-spherical uniformly distributed nanoconjugates of 
approximately 150 nm diameter (Figure 22). Hydrodynamic diameter (DLS) 
measurements were around 348 nm, whereas the SEM image showed smaller particle 
sizes. This difference is expected because DLS measures hydration and swelling of the 
conjugates in an aqueous phase, which results in increased diameters compared to the dry 
sample in SEM. The zeta potential of IRPDcov was -0.4±0.3 mV, due to charge 
neutralization during formulation. The nanoconjugates are soluble in aqueous solution, 
and PEG-mediated steric repulsion assists in preventing the formation of aggregates, with 
a solubility limit of approximately 2 mg IRPDcov/mL in deionized water.  
 
Figure 22. SEM image of IRPDcov. 
 
Particle yield was 74% for a 6k-PEG diamine formulation. IRPDcov fluorescent dye 
content was determined by spectrofluorometry to be approximately 0.113 mg IR820/mg 
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IRPDcov. Samples of IRPDcov in deuterated methanol were also analyzed by H-NMR, 
which confirmed conjugate formation. Figure 23 illustrates the H-NMR spectrum of the 
conjugate denoting the main identifiable peaks. The conjugate spectrum contains peaks 
contributed both from IR820 and PEG-diamine, which suggests that we have indeed 
made the conjugate. Any unreacted IR820 would have been removed during the dialysis 
process, so the presence of aromatic peaks (in the region between 7 and 9 ppm) indicates 
that the covalent linkage between IR820 and PEG-diamine was successful. It is important 
to note that there are small extra peaks in the spectrum that indicate that the sample is not 
completely pure, however, this can be attributed to the fact that IR820 is only available as 
a commercial grade chemical. 
 
Figure 23. H-NMR spectrum of IRPDcov in deuterated methanol. 
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5.1.1. Absorbance studies 
The UV-visible spectra of IR820, PEG-diamine and IRPDcov are shown in Figure 24. 
Concentrations of PEG-diamine and IR820 were chosen based on molar ratios used in the 
formulation of the nanocomplexes, and IRPDcov concentration was chosen to 
approximately match the concentration of the IR820 solution given the previously 
estimated dye content (0.113 mg IR820/mg IRPDcov). 
 
Figure 24. Absorption spectra of IR820 (solid black), IRPDcov (dashed black) and PEG-diamine (gray) in 
deionized water. 
 
IRPDcov displayed a bathochromic main absorption peak shift compared to IR820 
(IRPDcov λmax = 696 nm, IR820 λmax = 688 nm) as well as a shift in the secondary 
absorption peak (located at 836 nm for IRPDcov versus 815 nm for IR820). These shifts 
can be attributed to the formation of an extended π system by the conjugation process. 
There was also an overall broadening of the spectral profile. Increased absorption and 
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scattering within the environment of the nanoconjugate may explain the spectral 
observations. There were no peaks above 0.01 A.U. between 200 and 900 nm for PEG-
diamine at 24 μg/mL. The free dye spectrum showed a single peak at 688 nm with almost 
the same absorption intensity as the IRPDcov solution, confirming our dye content 
determination.  
5.1.2. Fluorescence properties of IRPDcov 
A representative fluorescence emission spectrum of IRPDcov after 785-nm excitation is 
shown in Figure 25 along with the corresponding profile for IR820 at comparable dye 
content. After 785-nm excitation, the peak emission for IRPDcov was located at 822 nm, 
with fluorescence intensity 6% smaller than IR820. The slight reduction in fluorescence 
intensity may be due to absorption of emitted fluorescence at secondary absorption peaks.  
 
Figure 25. Fluorescence spectra of IR820 and IRPDcov in phosphate buffered saline. 
 
In the case of IR820-PDNCs which were formulated by ionic interactions, fluorescence 
intensity of the conjugates was approximately 15% less than that of free dye. Therefore, 
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the covalent formulation demonstrates improved fluorescence with respect to the ionic 
formulation, likely by reducing unwanted interactions between IR820 and the buffer 
solvent.  
5.1.3. Fluorescence stability studies 
IRPDcov and IR820 solutions in buffer were measured up to 72 hours after preparation to 
determine the percent remaining fluorescent intensity compared to baseline. Samples 
were kept at 4°C in the dark. The decrease in fluorescence from baseline after 72 hours 
was significantly lower for IRPDcov (39.9% decrease) compared to IR820 (80% 
decrease), p<0.05. This indicates that covalent conjugation provides significant 
stabilization to the dye, likely as a result of increased rigidity of the IR820 molecule by 
incorporation into the nanoconjugate lattice, which would reduce intermolecular IR820 
aggregation. PEG-mediated steric hindrance may also play a role in preventing 
aggregation of IR820 molecules and the subsequent degradation process. The enhanced 
preservation of fluorescence properties also indicates that the conjugate is stable as 
formulated for at least 72 hours, based on the large differences in fluorescence observed 
between conjugate and free dye samples after that time period. 
5.2. Cell Imaging Studies 
Figure 26 shows fluorescence microscopy images of Dx5, SKOV-3 and MES-SA cell 
lines after 4 hours incubation at 5 μM concentration of IR820 and IRPDcov at equivalent 
dye content. This concentration was chosen based on our previous cellular studies with 
IR820 (Fernandez-Fernandez et al., 2012). In all three cell lines, intense fluorescence was 
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observed inside the cells after 4 hour incubation with IR820 or IRPDcov, indicating that 
both the free dye and the nanoconjugates were capable of entering the cells. However, the 
images taken after IRPDcov incubation showed higher normalized intensity ratios than 
those taken after incubation with equivalent concentrations of IR820, especially in Dx5. 
Normalized intensity ratios were 1.8 times larger for IRPDcov than for IR820 in Dx5, 1.4 
times larger in MES-SA, and 1.2 times larger in SKOV-3. 
 
Figure 26. Cellular imaging of Dx5 (A, B), SKOV-3 (C,D) and MES-SA cells (E,F) after 4 hour incubation 
with 5 μM dye content of IRPDcov (top) or IR820 (bottom); 60x, exposure time 4000 ms. 
We had previously discussed how PEG can enhance cell membrane interaction and 
increase cell internalization by osmoelastic coupling and formation of PEG-induced 
fusion vesicles (Yamazaki et al., 1990; Zhang et al., 2002). In the case of IRPDcov, this 
may be one of the contributing factors to the enhanced internalization shown by the 
fluorescent images, as direct contact with PEG is not necessary to induce such effects. In 
comparison to the ionic IR820-PDNCs, IRPDcov produce comparable increases in 
internalization for Dx5 (1.7 increase ionic, 1.8 covalent) and MES-SA (1.2 increase ionic, 
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1.4 covalent), and a smaller increase in SKOV-3 (2.1 increase ionic, 1.2 covalent). 
Taking into consideration the additional fact that incubation times were 2.5 hours for the 
ionic agent versus 4 hours for the covalent formulation, it seems that IRPDcov does not 
result in as much enhancement in cellular internalization as the ionic formulation. This is 
likely due to the fact that IRPDcov charge is near neutral, which would not facilitate 
interaction with the typically negatively-charged cancer cell membranes (Albanese et al., 
2012). Another factor that may account for the difference is that IRPDcov are larger in 
diameter than the ionic formulation, and this may cause slower diffusion through the cell 
membrane. Ionic IR820-PDNCs are smaller and have a small positive charge, which may 
result in increased interaction with negative membranes and larger increases in 
internalization based on a combination of size effects, osmotic stress, and charge effects. 
However, IRPDcov still show enhanced internalization compared to free dye, most likely 
as a result of the PEG-induced osmotic effect. We must also weigh that in vitro behavior 
is not the only important parameter to consider. Having a near neutral or zwitterionic 
nanoformulation has its own advantages, such as prolonged plasma half-lives and 
reduced clearance, which will be important for in vivo applications (Arvizo et al., 2011) 
and could render IRPDcov superior to IR820-PDNCs.  
5.3. Cytotoxicity and Hyperthermia Studies  
We tested IRPDcov to determine whether the dye in nanoconjugate form was still able to 
generate heat upon exposure to an 808-nm NIR laser. At a laser fluence rate of 8 W/cm2, 
a solution of 0.038 mg/ml IRPDcov (containing 5 μM IR820) caused an increase in 
temperature from 37°C to 42.2°C after 3 minutes of exposure, demonstrating that 
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covalent binding of IR820 did not interfere with heat generation properties. As previously 
discussed, this temperature is in the moderate hyperthermia range (41-43 °C) which can 
cause significant tumor cell growth inhibition but does not greatly affect healthy cells. 
We also tested PEG-diamine by itself, which did not result in significant changes in 
temperature after 3-minute laser exposure compared to wells containing medium only. 
Therefore, the IR820 component of the nanoconjugates is responsible for hyperthermia 
generation.  
 
SKOV-3, Dx5 and MES-SA cells were chosen to study the cytotoxic effect of IR820 and 
IRPDcov on tumor cells with and without hyperthermia. Figure 27 shows net cell growth 
following incubation with IR820 or IRPDcov, with or without exposure to laser, for 
SKOV-3, Dx5, and MES-SA. All groups were normalized to the control group not 
exposed to dye or laser.  
 
Without laser, IRPDcov demonstrates toxicity comparable to the free dye. There was no 
significant toxicity in SKOV-3 or Dx5 compared to the control group which was not 
exposed to IRPDcov or IR820, and there was a slight growth inhibition in MES-SA cells 
for IRPDcov treatment, consistent with our previous observations for IR820. There was 
no significant difference in net cell growth between the IR820 group and the IRPDcov 
group without laser exposure for any cell line, indicating that IRPDcov can be safely used 
up to at least 5 μM. From our previous studies, we determined that laser exposure by 
itself or PEG-diamine by itself did not cause any significant effect on cell growth for any 
of the three cell lines (Manchanda et al., 2012).  
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Figure 27. Cytotoxicity of IRPDcov or IR820 in cancer cell lines, with or without hyperthermia treatment 
at 5 μM dye concentration, n = 3 experiments, 4 wells/experiment. All groups are normalized to the control 
group not exposed to dye or laser. There was no significant effect of laser exposure per se without IRPDcov 
or IR820, and there was no significant effect of PEG-diamine exposed to laser.  * = significant difference 
(p<0.05) versus non-laser group, **= significant difference (p<0.05) between laser groups. 
 
When exposed to laser, cell growth was significantly inhibited in all three cell lines by 
both IR820 and IRPDcov. In MES-SA and Dx5 cell lines, IRPDcov hyperthermia 
resulted in significantly higher cytotoxicity (p< 0.05) compared to IR820. In the case of 
MES-SA, IRPDcov plus laser resulted in cell killing, versus IR820 plus laser which 
caused cell growth inhibition. In SKOV-3 cells, IRPDcov hyperthermia produced higher 
cytotoxicity than free dye, but not enough to reach statistical significance. Based on the 
cell imaging results displayed in Figure 26, there may be a larger degree of 
internalization for IRPDcov than for free dye. This is consistent with the increased 
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cytotoxicity effect of the hyperthermia treatment that can be observed in Figure 27. 
Enhanced internalization would result in larger accumulation of the dye inside the cell 
and an accentuated damaging effect of temperature increases within the cell. This seems 
to be most apparent in MES-SA cells, where laser exposure of cells treated with IRPDcov 
resulted in a cell killing effect.  
 
When comparing ionic IR820-PDNCs and covalent IRPDcov conjugates, there were no 
statistically significant differences in cell growth inhibition between the two 
formulations. For both conjugates, the hyperthermia enhanced cytotoxic effect versus free 
dye reached statistical significance in MES-SA and Dx5 cell lines, but not in SKOV-3. 
This further solidifies the hypothesis that there could an inherent insensitivity to 
hyperthermia in SKOV-3, possibly related to the p53 deletion mutation that could affect 
apoptotic responses. These results are consistent with similar observations reported by 
other researchers who were unable to induce death in SKOV3 cells by treating them with 
branched gold nanoparticles exposed to laser at 38 W/cm2 for 5 minutes with an 11°C 
temperature increase (Van de Broek et al., 2011), even though the thermal cross section 
of gold nanoparticles is higher than that of organic dyes (Yguerabide et al., 1998). It is 
apparent that SKOV-3 has inherent thermotolerance. Hyperthermia-induced cytotoxicity 
is controlled by both p53-dependent and-independent pathways (Fukami et al., 2004; 
Ohnishi et al., 2008; Sturm et al., 2006). Based on existing knowledge, thermosensitivity 
and thermotolerance depend on an array of biological, genetic, and environmental factors, 
so that a specific cause for SKOV-3 thermotolerance within the context of our studies 
cannot be determined. 
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As previously discussed in chapter 4, PEG-diamine by itself does not cause oxidative 
stress levels able to significantly affect cell growth after laser exposure. However, for 
both IR820-PDNCs and IRPDcov, our results showed an enhanced effect of hyperthermia 
in Dx5 and MES-SA cells. Increases in cell internalization may play a role in explaining 
this difference, but the co-localization of PEG-diamine and IR820 could also have an 
effect based on the fact that some mechanisms of cell death in hyperthermia are tied to 
oxidative stress responses (Li et al., 2001; Skibba et al., 1997; Wada et al., 2005; Yuki et 
al., 2003). IRPDcov nanoconjugates may provide advantages over IR820 alone based on 
simultaneous hyperthermia and free radical generation creating a toxic environment for 
cancer cells.   
5.4. Summary 
Under this specific aim, we successfully prepared nanocomplexes of IR820 and PEG-
diamine (IRPDcov) and investigated cellular uptake and cytotoxicity in cancer cell lines 
MES-SA, SKOV-3 and Dx5. The nanoconjugates were able to generate a cytotoxic 
hyperthermia effect, as well as to emit a fluorescence signal that can be used for imaging. 
The IPDcov formulation can potentially provide an advantage over the use of free agents 
by significantly enhancing the stability of the NIR dye, increasing cell internalization, 
allowing simultaneous co-localization of imaging and therapy, and accentuating the 
cytotoxic effect of hyperthermia. Additionally, the conjugate nanosize can provide the 
advantage of passive targeting by the EPR effect. The next step toward clinical 
application is performing animal studies to determine the behavior of the conjugate in 
vivo in terms of biodistribution and plasma pharmacokinetics. The expectation is that, due 
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to the presence of PEG, the nanoconjugate will have prolonged distribution and 
elimination half-lives with respect to the free dye, resulting in advantages for theranostic 
applications. 
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CHAPTER 6: BIODISTRIBUTION AND PHARMACOKINETIC STUDIES               
OF COVALENT IR820-PEG DIAMINE NANOCONJUGATE (IRPDcov), IR820, 
AND ICG IN MICE  
In vitro studies can provide valuable information, predicting the in vivo behavior of 
therapeutic agents by informing us of their physicochemical characteristics in an aqueous 
environment and inside cells, however, they cannot reflect the complexity of an actual 
living system. Studies using an animal model are the natural follow-up to in vitro studies 
of a molecule or agent that shows promise based on in vitro experimental results. In our 
case, we proceeded to study the biodistribution and pharmacokinetics of IRPDcov in a 
mouse model, and established a comparison with free IR820 as well as ICG in the same 
model. The questions we wanted to answer were: 
1. Can the IRPDcov conjugate be used for in vivo optical imaging? 
2. Is there any difference in biodistribution between IRPDcov, IR820, and ICG? 
3. Is there any difference in pharmacokinetic behavior of IRPDcov, IR820, and ICG 
in terms of half-life and other pharmacokinetic parameters? 
Biodistribution and pharmacokinetics studies are typically done in mice due to their low 
cost, ease of handling, and the valuable information they can provide. Mouse models 
have been successfully used in many instances of preclinical exploration to determine 
pharmacokinetic behavior and safety of drug candidates before they are tested in humans 
(European Commission, 2010). There are many examples in the literature of in vivo 
testing of optical and therapeutic agents, in their free forms as well as nanoformulations, 
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using mouse models. Some examples include studies of the pharmacokinetics of different 
formulations of paclitaxel (gel, film, prodrug, liposomes and micelles) in Swiss mice 
(Dhanikula et al., 2005); the biodistribution of ICG versus ICG-PLGA nanoparticles in 
C57BL/6 mice (Saxena et al., 2006); the biodistribution of ICG versus ICG-containing 
electrostatically assembled mesocapsules (MCs) in Swiss Webster mice (Yaseen et al., 
2009); the biodistribution of inorganic luminescent nanoparticles in healthy Swiss mice 
as well as tumor-bearing C57BL/6 mice (de Chermont et al., 2007); among countless 
others.  
 
Different models can be used in pharmacokinetic analysis to try to approximate the 
behavior of a molecular agent in vivo. In the compartmental approach, the researcher 
assumes that the drug will be distributed into one or more so called “compartments”, 
which represent distinct regions of the body, such as organs or body fluids (Fournier, 
2007). In this model, an input function represents drug administration, an output function 
represents drug clearance, and mass transfer can occur between compartments at specific 
rates (Truskey et al., 2009). 
 
The most straightforward approach to compartmental modeling is to assume the body is a 
single compartment. In one compartment models of i.v. bolus administration, the 
assumption is that the agent under study distributes uniformly in the body. A drug 
injection goes into the “central compartment”, which has a specific volume, and is 
eliminated by either inactivation of the agent by metabolism, or excretion in urine and 
feces (Truskey et al., 2009).   
96 
 
A one-compartment model is illustrated in figure 28. 
 
Figure 28. Exemplification of a one-compartment model for pharmacokinetic studies. 
 
Concentration of a molecule over time in one-compartment models can be represented 
mathematically by a monoexponential decay equation of the form 
C(t)=C0*e
-kt       Equation 4 
 
where C(t) is the concentration as a function of time, C0 is the modeled initial 
concentration, k is the rate constant for clearance, and t is time. The rate constant can be 
used to calculate half-life, the amount of time it takes for 50% of the agent to disappear 
from the system, as follows: 
     t1/2 =
ln (2)
k
          Equation 5 
 
A more complex approach is the two-compartment model, which takes into account the 
fact that molecule transport in plasma is often different from transport in tissue. In a two 
compartment model of i.v. bolus administration, the central compartment represents 
plasma and well-perfused organs such as the liver, whereas another compartment called 
the peripheral compartment represents other organs which uptake the agent (Truskey et 
al., 2009). The input injection and the output clearance are still assumed to be happening 
to and from the central compartment, but there is also bidirectional mass transfer between 
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the central compartment and the peripheral compartment (Fournier, 2007). Figure 29 
illustrates the concept of a two-compartment model. 
 
Figure 29. Exemplification of a two-compartment model for pharmacokinetic studies. 
 
In a two-compartment model, pharmacokinetic behavior is biphasic and is characterized 
by two distinct phases called distribution and elimination. In the initial distribution phase, 
the agent rapidly equilibrates in solution in the central compartment comprised of plasma 
and other fluids, and is simultaneously (1) being eliminated from the central compartment 
by liver metabolism and kidney excretion, and (2) moving towards or distributing into  
the peripheral compartment comprised of other tissues (Bauer, 2008; Truskey et al., 
2009). Although elimination occurs during this phase, the governing process is 
distribution. The initial distribution phase corresponds to rapidly declining plasma 
concentrations. At the end of this phase, both compartments momentarily equilibrate 
reaching steady state, but the concentration gradient is quickly reversed by the fact that 
elimination continues to occur in the central compartment, and the second phase starts.  
In the subsequent slowly-progressing second phase, the predominant process is 
elimination, as the agent is redistributed from the peripheral compartment to the central 
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compartment and is eventually cleared from the body (Bauer, 2008; Fournier, 2007). 
Concentration vs. time profiles in a two-compartment model can be represented 
mathematically by a bi-exponential decay equation of the form: 
C(t)=A*e-at+B*e-bt       Equation 6 
 
where C(t) is the concentration as a function of time, A and B are constants whose sum 
models the initial concentration, a is the rate constant for distribution, b is the rate 
constant for elimination, and t is time (Truskey et al., 2009). From this model, we can 
calculate two separate half-lives, one for distribution (initial, rapidly-declining phase) and 
one for elimination (slower second phase), based on their corresponding time constants. 
The distribution half-life is given by 
t1/2 =
ln 2
a
          Equation 7 
 
And the elimination half-life is given by 
t1/2 =
ln 2
b
          Equation 8 
 
For small molecules, higher order compartmental models with a larger number of 
compartments may be appropriate to fully understand their behavior in different tissues 
(Truskey et al., 2009). In this case, one would follow the same exponential decay models 
that were previously described, but with additional terms representing mass transfer 
between different compartments. 
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As is the case for any model, compartmental models are obviously an oversimplification 
of a living system. The choice of a specific compartmental model to represent a set of 
data is commonly dictated by expected physiological behavior, the goodness of fit 
between data and model, and the degree of improvement in fit when a higher order model 
is used. Although a higher order model will often give a better fit, the improvement may 
not be significant enough to justify the introduction of complexity into the model, and 
there are some inherent dangers in “overfitting” data, such as creating a model that 
cannot be generalized (Zuegge et al., 2001). The common approach in the absence of 
prior knowledge to guide the researcher seems to be to start with the simplest model 
possible, including those reported for agents that could theoretically have a similar 
behavior. One can then progress toward increasingly complex models until a satisfactory 
fit is achieved. 
 
A way to interpret goodness of fit is to look at the root mean square error (RMSE). Given 
the error E as the difference between experimental data and predicted data at a given time 
point t, the RMSE is calculated as: 
RMSE=�1
n
∑ (Ei)2ti=0    Equation 9 
 
The advantage of the RMSE is that it is given in the same units as the original data, so 
that it can provide a representation of the size of the average error. As a way to determine 
the percent error inherent in our model -and thus in parameters that are computed from 
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said model- we can use the root mean square percentage error (RMSPE). To calculate 
RMSPE, we calculate the percent error for each prediction and compute RMSPE as: 
 
PE=100* predicted value-observed value
observed value
    Equation 10 
RMSPE=�1
n
∑ (PEi)2ti=0           Equation 11 
 
Obtaining the value of RMSPE allows us to estimate the percent error that is to be 
expected in parameters derived from model equations. 
 
6.1. Study Design 
Thirty-six healthy ND4 Swiss-Webster outbred mice, weighing between 25 and 30 
grams, were purchased from Harlan (Indianapolis, IN). Animals were housed at the FIU 
Animal Care Facility under a 12-hour light/dark cycle and fed ad libitum. All IUCAC 
regulations were followed. Table 5 reflects group assignments.  
 
        15 minutes 30 minutes 60 minutes 24 hours 
IRPDcov Group 1 Group 4 Group 7 Group 10 
IR820 Group 2 Group 5 Group 8 Group 11 
ICG Group 3 Group 6 Group 9 Group 12 
 
Table 5. Study design for biodistribution experiments of IRPDcov, IR820 and ICG in mice. Each group 
was comprised of 3 mice. 
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Mice were randomly assigned to groups based on optical agent (ICG, IR820, or 
IRPDcov), and time point of data collection after injection (15 minutes, 30 minutes, 60 
minutes, and 24 hours). Random assignment was performed by card draw, with n=3 for 
each group. 
 
6.2. Specific Methodology 
6.2.1. Injection and dosage 
The literature recommends that a safe i.v. injection volume for mice is 0.2 mL 
(Wolfensohn et al., 2003), and other authors have used a 0.24 mg/kg dose of dye for 
studies of optical agents in mice (Rajagopalan et al., 2000). Following these guidelines, 
animals were weighed and the appropriate solution concentration for this injection 
volume based on desired dosage was calculated as follows:  
a. For free dye, we used a 0.24 mg/kg dose, i.e.: 
Injection mass=(mouse weight in kg)* �0.24 mg
kg
� 
Solution concentration=
injection mass
0.2 mL
 
b. For conjugate, we used a 0.24 mg dye/kg dose by adjusting for conjugate dye 
content, as follows:  
Injection mass=(mouse weight in kg)* �0.24 mg
kg
� *( mg dye
mg conjugate
)            
Solution concentration=
injection mass
0.2 mL
 
For example: for a 25-g mouse, 
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  0.025 kg* 0.24 mg IR820
kg
* 1 mg IRPDcov
0.113 mg IR820
 = 0.053 mg IR820PDcov 
For an injection volume of 0.2 mL,  
need solution of  
 0.053 mg IRPDcov
0.2 mL
=0.265
mg IRPDcov
mL
  
 
Solutions for injection were prepared by first dissolving the agents in small volumes of 
deionized water, and then diluting in saline solution to the final desired concentration. 
Then, 0.2 mL of the solution was placed in a 1-mL syringe with a 30g needle, and the 
syringe was covered with aluminum foil to protect it from light. The use of a 30g needle 
(instead of the 26g needles utilized in the rat studies) was chosen to accommodate the 
smaller diameter and size of the mouse tail veins. Also, because of the small volumes 
allowed, no flushing was performed and a direct method of injection was used instead of 
the three-way stopcock method we had utilized in rats. Before the injection, an infrared 
lamp was used to warm the tail, dilate the veins and facilitate visual localization of the 
injection site. 
6.2.2. Time sequence of blood and organ sampling 
Mice in groups 1-9 were anesthetized with i.p. pentobarbital (100 mg/kg obtained from a 
10 mg/mL stock solution), shaved, placed supine on the imaging setup, injected through 
the tail vein with their assigned agent, and imaged. At the predetermined time point while 
under anesthesia, a blood sample was obtained by heart puncture into the ventricle, and 
the animal was then euthanized by removal of the heart. For mice in groups 4-9, the 
pentobarbital dose was given in two injections, the first 50 mg/kg before imaging, and the 
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second 50 mg/kg administered 15 minutes before the terminal time point. The dose was 
split in this manner, rather than given in a single dose, in order to ensure survival until the 
terminal time point. For mice in groups 10-12, each animal was anesthetized with 40 
mg/kg of i.p. pentobarbital, injected with the assigned agent, and imaged. These mice 
were then returned to their cage alive until the 24-hour time point. After 24 hours, they 
were anesthetized with 100 mg/kg of i.p. pentobarbital and imaged again under the same 
operating conditions. After imaging, a blood sample was obtained by heart puncture, and 
organs were carefully harvested for imaging and subsequent homogenization and dye 
extraction. These animals were finally euthanized by removal of the heart. 
 
6.2.3. In vivo imaging techniques 
The same general techniques for animal and organ imaging that were described in chapter 
2 were followed for the mice studies, including the setup used and the software for 
processing the data.   
 
6.2.4. Plasma and organ sample processing 
Plasma and organ sample processing followed the procedures described by other 
researchers who have performed biodistribution studies of NIR dyes and related 
compounds (Saxena et al., 2006; Yaseen et al., 2009). In the case of blood samples, 
immediately after collection the samples were centrifuged 2x for 3 minutes at 12,000 rpm 
to extract plasma.  Plasma samples were then incubated in DMSO (1 plasma: 50 DMSO) 
in glass vials covered with aluminum foil for thirty minutes and centrifuged again. The 
resulting supernatant was used to perform spectrofluorometric measurements of dye 
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concentration in plasma using a previously created calibration curve of IR820 or ICG in 
DMSO at 785-nm excitation.  
 
For organ samples in the 24-hour groups, organs were carefully dissected and placed in 
black-coated Petri dishes for imaging as previously described for our rat studies. 
Fluorescent organs were then cut into small pieces using a scalpel, placed in pre-weighed 
glass vials, and homogenized using a tissue homogenizer. The vials with homogenized 
samples were reweighed, and 5 mL of DMSO was added for dye extraction. Samples 
were incubated in DMSO for 4 hours covered with aluminum foil, and centrifuged at 
9,000 rpm for 15 minutes. The supernatant was used to perform spectrofluorometric 
measurements of dye content using a previously created calibration curve of IR820 or 
ICG in DMSO at 785-nm excitation. To report the data, organ dye content was 
normalized to organ mass. 
 
6.2.5. Pharmacokinetic analysis of plasma data 
Dye concentration in plasma obtained from spectrofluorometer measurements was 
averaged for each group, and the average concentration for each time point was entered 
into Matlab (MathWorks, Natick, MA). The initial concentration (concentration at 
injection) was estimated for an average 25-g mouse. The injected amount was 
approximately 6 µg dye based on the 0.24 mg/kg standardized dosage, with a mouse 
plasma volume of approximately 1.5 mL based on literature ratios of 58.5 mL plasma /kg 
body weight (Macon et al., 2011). This results in an initial concentration of 
approximately 4 µg dye/mL in plasma.  
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Using the curvefit tool in Matlab, average data points at 0, 15, 30, 60 minutes, and 24 
hours were fit to both monoexponential and biexponential curves via a least squares 
algorithm. As discussed before, researchers attempting to model pharmacokinetic 
behavior often choose to start with the simplest model that is theoretically sound for a 
given set of experimental data, and progress to more complicated models as needed based 
on fit results. In our case, literature shows that ICG pharmacokinetics have been modeled 
by other authors with either a one-compartment or a two-compartment model approach 
(Achilefu et al., 2002). Given these sources, there is justification to attempt to fit the data 
for ICG, IR820, and IRPDcov to monoexponential and biexponential curves as an initial 
approach. We do not truly know if these will be appropriate for IR820 and IRPDcov, 
because nothing has been reported in the literature regarding IR820 pharmacokinetics, 
and IRPDcov is a novel conjugate. Regardless, it seems wise to start our modeling efforts 
by utilizing what has been reported by others for ICG. We would expect the behavior of 
these agents to be somewhat similar to ICG, especially in the case of IR820. Thus, we 
focused on one-compartment and two-compartment pharmacokinetic models. The 
resulting monoexponential and biexponential fit equations were used to determine the 
overall half-life (in the case of the monoexponential model), or the half-lives of 
distribution and elimination (in the case of the biexponential model). Other calculated 
pharmacokinetic values included the area under the pharmacokinetic curve, the mean 
plasma residence time, and the clearance rate.  
 
The area under the curve (AUC) is the integral of the concentration vs. time curve, which 
we calculated using Simpson’s rule.  
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Area under the curve= AUC= ∫ C(t)dt
∞
0   Equation 12 
 
The mean residence time in plasma, tp, is the average time spent by the agent of interest 
in plasma, and is given in its simplest expression by: 
Mean plasma residence time=tp=
AUC
C0
    Equation 13 
 
where C0 is the modeled original concentration. This value corresponds to the coefficient 
C0 in a monoexponential model, and to the sum of coefficients A+B in a biexponential 
model.  
 
The total body clearance rate (i.e. volume of agent cleared from the body per unit time) is 
given by: 
Total body clearance rate= Dose
AUC
   Equation 14 
 
Based on the preceding calculations, we compared IRPDcov, IR820 and ICG 
pharmacokinetic parameters using one-way ANOVA (p<0.05) followed by Bonferroni 
post-hoc test. 
 
6.3. Results and Discussion 
6.3.1. Animal imaging  
Figure 30 shows representative images obtained from ICG, IR820, and IRPDcov animals 
15 minutes and 24 hours after injection. 
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Figure 30. Images taken 15 minutes and 24 hours after i.v. injection for IRPDcov, IR820, and ICG. 
 
These images prove that IRPDcov can be used for in vivo imaging and that it provides an 
imaging signal comparable to that of IR820. As expected based on our prior rat imaging 
experiments, the signal ratio for ICG at 15 minutes after injection was higher than that of 
IR820 or IRPDcov. However, in agreement with our previous data, by 24 hours the 
intensity of ICG had dropped significantly in comparison with the other two agents.  The 
24-hour ICG signal also seemed to be located in the lower abdomen, instead of in the 
liver region as is the case for the other two agents. 
 
6.3.2. Organ imaging 
Organ images obtained after 24 hours demonstrate a very different biodistribution for 
ICG compared to the other two agents. Figure 31 provides a qualitative comparison of 
organ signals for IRPDcov, IR820, and ICG, and Table 6 summarizes the organ signal 
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intensity per unit area ratios for each dye. The information obtained from the ratio data 
indicates that the biodistribution of IRPDcov, IR820, and ICG shows a different pattern 
between agents 24 hours after i.v. injection. 
 
 Image intensity per area, R (1/µm2) 
 IRPDcov IR820 ICG 
Liver 6.35±0.44*(p<0.001) 6.13±1.44* (p=0.002) 0.76±0.35 
Lungs   **(p=0.003) 0.64±0.08*(p=0.04)  2.48±0.47* (p=0.001) 0.18±0.32 
Kidneys 1.34±0.13*(p=0.003) 2.95±1.88*(p=0.04) 0.20±0.34 
Intestines 0.65±0.10  1.00±0.45 2.01±1.43 
 
Table 6. Signal intensity ratios for liver, lungs, kidneys and intestines collected 24 hours after i.v. injection 
of IRPDcov, IR820, or ICG. Values represent average±SD. * = Significant difference (p<0.05) with ICG 
values for the same organ; ** = Significant difference (p<0.05) between IRPDcov and IR820 values for the 
same organ. 
 
Although an ICG signal was still present in the liver, the ratio was significantly lower 
(p<0.05) than for IR820 or IRPDcov. The amount of ICG present in the kidneys and the 
lungs was also significantly smaller (p<0.05) than for the other two agents. In the case of 
the intestines, a higher signal was observed for ICG than for IR820 or IRPDcov, 
however, the effect did not reach statistical significance due to large standard deviation 
for ICG measurements in the intestines.  We expect that inter-subject variability in 
intestinal motility rates would affect ICG more markedly, given that most of the dye is 
being eliminated via the gastrointestinal tract at the 24-hour time point. 
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Figure 31. Organ images taken 24 hours after i.v. injection of IRPDcov, IR820, or ICG. 
 
In the case of IR820, a strong signal was observed in the liver, kidneys, and lungs, with a 
small signal in the intestines. IRPDcov showed a strong signal in the liver, some signal in 
the kidneys, and a small signal in lungs and intestines. Statistical analysis comparing 
IR820 and IRPDcov showed that there were no differences in liver or intestinal image 
ratios. There was a significant difference (p<0.05) in lung image ratios, with IRPDcov 
showing a smaller signal ratio than IR820. This possibly indicates that the 
nanoformulation was able to escape detection by alveolar macrophages thanks to the 
presence of PEG, which reduces binding to serum proteins (Li et al., 2008). In the 
kidneys, the IRPDcov signal was smaller than that of IR820, but the difference did not 
reach statistical significance. There may be a somewhat smaller degree of elimination of 
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IRPDcov through the kidneys, which would be consistent with the expectation that the 
larger size of the conjugate compared with the free dye would result in decreased renal 
clearance based on a low molecular size cutoff for renal excretion (Li et al., 2008), as 
well as the fact that the presence of PEG could result in reduced reticuloendothelial 
system uptake. However, the small number of subjects in our study may not provide 
enough sensitivity to detect a significant difference. Another reason for the lack of 
significance could be variability in renal elimination rates between subjects. Additionally, 
imaging ratios may not be sensitive enough to detect quantitative differences. 
 
From these images we can conclude that there are clear differences in the biodistribution 
patterns of ICG versus IRPDcov and IR820, with ICG being more rapidly cleared from 
major organs than the other two agents, and primarily localizing in fecal elimination 
pathways by 24 hours. In terms of comparing IRPDcov with IR820, our lung images 
support the hypothesis of reduced mononuclear phagocyte system uptake (Li et al., 
2008), which we can probably owe to the presence of PEG. Additionally, it is possible 
that further studies with larger numbers of subjects could also detect reduced localization 
to the kidneys. 
 
6.3.3. Organ dye content  
Table 7 shows the average dye content in µg dye/g tissue for liver, lungs, kidneys and 
intestines 24 hours after an i.v. injection of IRPDcov, IR820, or ICG. The data is 
consistent with our qualitative observations and quantitative signal ratios from the optical 
imaging samples, and provides increased sensitivity to detect differences.  
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 Organ dye content (µg dye/g tissue) 
 IRPDcov IR820 ICG 
Liver 0.25 (4.1%)±0.03* 0.21(3.6%)±0.11* 0.01(0.6%)±0.003 
Lungs** 0.12(2.0%)±0.02* 0.28(4.7%)±0.03*  0 - Background signal 
Kidneys 0.31(5.2%)±0.10* 0.42(6.9%)±0.11* 0 - Background signal 
Intestines 0.03(0.5%)±0.01* 0.05(0.8%)±0.01* 0.07(1.2%)±0.02 
Table 7. Quantitative organ content 24 hours after after i.v. injection of IRPDcov, IR820, or ICG.                
Values represent average±SD(%ID). * = Significant difference (p<0.05) with ICG values for the same 
organ; ** = Significant difference (p<0.05) between IRPDcov and IR820 values for the same organ 
 
When we compare the results for ICG with those of IRPDcov and IR820, we see that 
organ content was significantly higher in the intestines, and significantly lower in all 
other organs. For lung and kidneys, ICG sample readings were at background level. 
When comparing IRPDcov and IR820, the only significant difference was a reduced 
content of IRPDcov in the lungs. IRPDcov kidney content was lower than for IR820, but 
the difference was not significant. Thus, the interpretation presented in section 6.3.2. is 
supported by our quantitative analysis of organ dye content. Additionally, the difference 
between intestinal uptake of ICG, IRPDcov, and IR820 becomes significant once 
quantitative organ dye content was used as a measurement. 
 
6.3.4. Plasma dye concentration 
Table 8 shows the average dye concentration in plasma in µg/mL for IRPDcov, IR820, 
and ICG at each of the time points under study. We observed significantly higher 
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(p<0.05) plasma concentrations of IR820 and IRPDcov compared to ICG for all time 
points, with plasma values 20 times higher at 24 hours for IRPDcov, and 10 times higher 
for IR820. We also found significantly higher (p<0.05) concentrations of IRPDcov 
compared to IR820 at the 30-minute, 60-minute, and 24-hour time points, with plasma 
concentration of IRPDcov double that of IR820 at the 24-hour sampling time.   
 
 Dye 
Time  IRPDcov IR820 ICG 
15 minutes 2.52±0.99*(p=0.008) 1.94±1.17*(p=0.03) 0.20±0.16 
30 minutes **(p=0.01) 1.80±0.29*(p<0.001) 0.97±0.15*(p<0.001) 0.07±0.004 
60 minutes **(p<0.001) 0.83±0.03*(p<0.001) 0.34±0.03*(p<0.001) 0.05±0.02 
24 hours **(p<0.001) 0.20±0.02*(p<0.001) 0.10±0.01*(p<0.001) 0.01±0.003 
 
Table 8. Plasma concentrations (µg/mL) of IRPDcov, IR820, and ICG at different time points after i.v. 
injection. Values represent average±SD. * = significant difference from ICG, p<0.05; ** = significant 
difference between IRPDcov and IR820, p<0.05. 
 
Based on these results, not only were IR820 formulations superior to ICG as expected in 
terms of plasma concentration over time, but we also observed a clear advantage of the 
IRPDcov conjugate over IR820 after initial distribution. This confirms the applicability 
of the theoretical foundation that justified the formulation of this conjugate, which relied 
on the possibility that the presence of PEG could contribute to improved plasma 
concentration profiles by reducing detection by macrophages and other circulating agents 
in plasma.  IRPDcov is thus analogous to other formulations where the inclusion of PEG 
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has provided some stealth characteristics in an in vivo environment. The differences 
observed between IR820 and IRPDcov are most likely due to differences in charge, size, 
and surface characteristics, which are discussed in section 6.2.5. 
 
The recovered percent injected dose at 24 hours in plasma was 3.3% for IRPDcov, 1.7% 
for IR820, and 0.8% for ICG. If we add these numbers to the percent values of the 
recovered injected doses found in our organ content studies, we reach an overall percent 
of 15.1% for IRPDcov, 17.7% for IR820, and 2.6% for ICG.  
 
In the case of ICG, almost the entire injected dose has been lost after 24 hours, which 
demonstrates a clear advantage of the IR820 formulations in terms of injected dose 
recovery at this time point. Surprisingly, we did not observe a larger percent dose 
recovery for IRPDcov compared to IR820. A possible explanation may be that, as the 
circulating concentration of IRPDcov is still double that of IR820 at 24 hours, it is 
possible that a considerable amount of the conjugate may yet be present in other non-
sampled tissues, such as fat, skin, muscle, bone, or the lymphatic system. 
 
6.3.5. Pharmacokinetic modeling 
Figure 32 below shows a representative screenshot of the Matlab curvefit tool. All dyes 
were fit to both a monoexponential and a biexponential model, and goodness of fit was 
assessed by R2, RMSE, and calculated RMSPE.  The latter two were calculated as 
previously described by comparing model predictions with experimental data. 
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Figure 32. Sample curve fit for plasma concentration data using the curvefit tool in Matlab 
 
Figure 33 shows the plasma pharmacokinetic profiles for IRPDcov, IR820, and ICG, in a 
graph created using Sigmaplot (Systat Software, San Jose, CA). 
 
Figure 33. Pharmacokinetics of IRPDcov, IR820, and ICG plasma concentrations vs. time after i.v. dose.  
 
a. One-compartment modeling  
Table 9 shows the resulting parameters from a one-compartment modeling approach to 
IRPDcov, IR820, and ICG data, given the monoexponential equation:  
C(t)=C0*e
-kt 
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 IRPDcov IR820 ICG 
Model equation C(t)=3.952*e-1.619t C(t)=3.984*e-2.805t C(t)=4*e-11.87t 
R2 0.9912 0.9971 0.999 
RMSE 0.1396 0.0848 0.0434 
RMPSE 2.40% 2.00% 1.94% 
Half-life (hours) 0.428±0.010 †, †† 0.247±0.005†, †† 0.058±0.001 
AUC [µg-h/mL)] 2.441±0.059†, †† 1.420±0.028†, †† 0.340±0.007 
Mean plasma 
residence time, tp  (h) 
0.610±0.015†, †† 0.355±0.007†, †† 0.085±0.002 
Total body clearance 
rate (ml/h) 
2.46±0.06†, †† 4.22±0.08†, †† 17.6±0.34 
Table 9. Pharmacokinetic parameters from one-compartment analysis of dye data in mice. † = significant 
difference (p<0.05) with ICG; †† = significant difference (p<0.05) between IRPDcov and IR820. 
The monoexponential model provided a good fit to our data, with R2 values over 0.99 for 
all dyes, and percent errors under 2.5%. According to this model, both IR820 and 
IRPDcov demonstrate significantly longer half-lives, larger AUC, longer tp, and slower 
body clearance rates than ICG. All of these are signs of prolonged blood circulation (Li et 
al., 2008). Additionally, IRPDcov also showed a significant advantage over IR820 for all 
of these parameters, indicating that the nanoformulation resides longer in plasma and is 
eliminated from the body more slowly. However, it seems that the calculated clearance 
rates represent quite large volumes for a mouse, which leads us to question the 
physiological validity of the model. 
 
b. Two-compartment modeling 
Table 10 shows the resulting parameters from a two-compartment modeling approach to 
IRPDcov, IR820, and ICG data, given the biexponential equation:  
C(t)=A*e-at+B*e-bt 
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 IRPDcov IR820 ICG 
Model equation 
based on plasma data 
C(t)=3.666*e-1.905t 
+0.3162*e-0.01955t 
C(t)=3.831*e-3.108t 
+0.1702*e-0.02275t 
C(t)=3.927*e-13.54t 
+0.0734*e-0.3752t 
R2 0.9953 0.9999 0.9999 
RMSE 0.1023 0.0120 0.0094 
RMPSE 1.59% 1.49% 1.51% 
Distribution half-life 
(h) 
0.364±0.006†, †† 0.223±0.003†, †† 0.051±0.001  
Elimination half-life 
(h) 
35.46±0.56†, †† 30.45±0.45†, †† 1.85±0.03  
AUC [µg-h/mL)] 7.98±0.13†, †† 4.38±0.07†, †† 0.490±0.007 
Mean residence time 
in plasma  (h) 
1.99±0.03†, †† 1.09±0.02†, †† 0.12±0.002  
Total body clearance 
rate  (ml/h) 
0.75±0.01†, †† 1.37±0.02†, †† 12.25±0.18 
Table 10. Pharmacokinetic parameters from two-compartment analysis of dye data in mice. † = significant 
difference (p<0.05) with ICG; †† = significant difference (p<0.05) between IRPDcov and IR820. 
As can be seen in Table 10, the biexponential model modestly improved the fit for 
IRPDcov in terms of R2 values compared to the monoexponential model, and did not 
improve the fit for IR820 and ICG, which was expected because the value of R2 was 
already very good for both dyes in the monoexponential model. The percent errors 
inherent in the biexponential model are all 1.6% and lower, which is a reduction from the 
monoexponential model. Total body clearance rates seem more physiologically plausible.  
 
Based on this, it seems that the biexponential model may provide a better understanding 
of our data. It can also provide us with separate insight into the distribution and 
elimination behavior of each agent, and allow further comparisons between formulations. 
According to this model, both IR820 and IRPDcov demonstrate significantly longer 
(p<0.05) distribution half-lives, longer elimination half-lives, larger AUC, longer plasma 
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residence times, and slower body clearance rates than ICG. Although distribution 
happens quite fast for all agents, ICG distribution half-life is approximately 3.06 minutes, 
whereas the value for IR820 is 13.4 minutes, and for IRPDcov 21.8 minutes. The value of 
distribution half-life for ICG is consistent with that previously reported by other authors, 
which ranges from 2 to 4 minutes (Desmettre et al., 2000; Mordon et al., 1998). The 
calculated elimination half-lives for IRPDcov and IR820, which both exceed 30 hours, is 
in stark contrast with that of ICG, which is 1.85 hours. These values are also well aligned 
with some of the conclusions reached by Prajapati’s group, who determined that IR820 
binds to albumin and should have a clearance half-life close to that of albumin, which is 
in the order of 35 hours (Prajapati et al., 2009). The elimination half-life value we 
obtained for ICG is consistent with literature data, as other authors report an elimination 
half-life of over 1 hour at low concentrations (Desmettre et al., 2000).  
 
Both the distribution and the elimination phases show improved profiles for IR820 
formulations compared to ICG in terms of providing a wider time window for theranostic 
action. As far as the area under the concentration-time curve, both IRPDcov and IR820 
are an order of magnitude larger than ICG, indicating an increased overall exposure to the 
theranostic agent. Additionally, IRPDcov also shows a significant advantage (p<0.05) 
over IR820 for all the above calculated parameters, with almost double the AUC and the 
mean plasma resident time of IR820, and almost half the clearance rate of IR820. The 
nanoformulation is present in plasma for longer periods of time, eliminated more slowly 
from the body, and the cumulative exposure of body compartments to the conjugate is 
larger than for any of the two free dyes. The time that the IRPDcov is bioavailable is also 
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significantly longer, as the elimination half-life of IRPDcov is 1.16 times longer than that 
of IR820, and 19 times longer than that of ICG; whereas the distribution half-life of 
IRPDcov is 1.6 times longer than that of IR820, and 7 times longer than that of ICG.  
 
Given that the enhanced permeability and retention effect is proportional to the time and 
amount of agent circulating in blood (Saxena et al., 2006), we would theoretically expect 
IRPDcov to result in a greater amount of dye accumulated and retained in tumors. 
However, further studies in a tumor-bearing model would be needed to explore this 
possibility. 
 
Other authors have studied the pharmacokinetics of nanoformulations and the general 
consensus is that nanoformulations may result in improved pharmacokinetic profiles, in 
many cases as a result of stabilization of the drug and reduced liver metabolism and renal 
clearance (Li et al., 2008). Still, loss of nanocomplexes from the circulation can occur by 
binding to serum proteins in the process known as surface opsonization, which 
subsequently causes recognition and removal by circulating phagocytes or macrophages 
(Albanese et al., 2012; Moghimi et al., 2012). In the case of PEGylated formulations, 
steric hindrance reduces the degree of protein binding, resulting in prolonged circulation 
times and giving PEGylated formulations an improved pharmacokinetic profile compared 
to their non-PEGylated counterparts (Albanese et al., 2012; Li et al., 2008). This seems to 
be applicable to formulations incorporating PEG as a conjugated moiety as is the case of 
the IRPDcov conjugate.  
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Another consideration which is intimately tied to these profiles is the surface charge of 
the formulation. Our nanoconjugates are zwitterionic, presenting both positive and 
negative charges and with an overall zeta potential that approaches neutrality. Other 
authors have found that, for other physical characteristics being similar, neutral and 
zwitterionic nanoformulations exhibit prolonged plasma half-lives and reduced clearance 
compared to largely positive or largely negative formulations, which indicates that charge 
may play a large role in maximizing circulation time (Arvizo et al., 2011).  
 
Nanocomplex size also has an effect on circulation time, with particles around 100 nm 
diameter demonstrating longer blood circulation profiles than larger or smaller particle 
sizes (Li et al., 2008). Liu et al studied the effect of size on biodistribution of liposomes, 
and found that sizes between 100 and 200 nm were present in circulation for longer times 
than those greater than 250 nm or smaller than 50 nm (Liu et al., 1992). Given that our 
nanoconjugates are around 150 nm per SEM measurement, it seems that size is also 
contributing to their prolonged circulation times. 
 
6.3.6. Limitations 
Our analysis is not without possible limitations. First, the pharmacokinetic models we 
have used have important assumptions such as uniform distribution, no absorption, rapid 
equilibration before sampling, and no degradation. Uniform distribution may be an issue, 
as we know that nanoformulations are distributed to tissues depending on pore size, in a 
different manner than their free form counterparts (Cho et al., 2008; Dhanikula et al., 
2005; Li et al., 2008). Regarding absorption, both the monoexponential and biexponential 
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models were good fits for our data and they both ignore absorption, thus we are quite 
confident that absorption is negligible enough to not impact our interpretation of the data. 
In terms of rapid equilibration, others have reported that equilibration of injected 
solutions in mice plasma can be assumed to happen within 2 minutes (Berezhkovskiy, 
2009). Since our first sample was taken at 15 minutes, we can assume that equilibration 
has occurred by that time, and we do not expect this assumption to be broken. Regarding 
the possibility of degradation into other byproducts, other authors have shown that ICG is 
mostly excreted in its intact form in bile (Achilefu et al., 2000; Saxena et al., 2006). Our 
in vitro studies show that IRPDcov conjugates are very stable and retain their 
characteristics for at least 72 hours in phosphate buffered saline. Based on this, we do not 
expect degradation to be a significant concern within the time periods studied in vivo. 
However, the in vivo environment cannot be fully mimicked by in vitro conditions, and 
some in vivo factors such as the presence of plasma proteins, reticuloendothelial system 
scavengers, and metabolism in liver or other tissues may result in aggregation, 
degradation, or changes in the structure of these molecules.  
 
A final consideration in terms of calculated pharmacokinetic parameters is the recent 
discussion regarding classical estimates of plasma residence time versus newer estimates 
that adjust for drug or agent elimination during the initial distribution period. 
Berezhvosky has proposed a revised plasma residence time equation that takes into 
consideration the time that it takes to reach a uniform plasma distribution 
(Berezhkovskiy, 2009). When we repeated our calculations using his equation, the values 
of plasma residence time for IRPDcov, IR820, and ICG were all within 0.02 hours of the 
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values we calculated using classical equations. Thus, although the revised equation may 
be useful for agents that have initial extremely rapid elimination profiles, we are 
confident that this is not a significant issue in the case of IRPDcov, IR820, or ICG, and 
we have chosen to report the classically calculated values of plasma residence time as a 
function of AUC and initial estimate of concentration. Moreover, the fact that our values 
barely changed using either of the two calculation approaches also provides some 
confidence that our assumed initial concentration in plasma is likely to be reasonably 
accurate.  
 
There are other concerns besides those arising from the models we used to approximate 
the in vivo pharmacokinetics of these agents. An important one may be the fact that we 
used parallel sampling, in which each data point is an isolated animal, rather than serial 
sampling, where samples are taken from the same animal over time. Although serial 
sampling has the advantage of reducing inter-subject variability in the concentration vs. 
time curves, it also puts the subjects at risk due to repeated blood sampling based on the 
procedure itself as well as the cumulative amount of blood lost that could lead to 
hypovolemic shock (Wolfensohn et al., 2003). Blood collection by heart puncture is best 
considered a terminal collection method (Hoff, 2000), and the alternative which is 
typically tail blood collection may not give us correct information as there is the potential 
for residual dye contamination of the tail. The fact that we achieved good model fits 
using parallel sampling seems to indicate that no large inter-subject variations were 
introduced by the method we used.  
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Another concern is the inability to flush the tail due to injection volume limitations. Other 
authors have reported that a large amount of sample can be left in the tail vein (Yaseen et 
al., 2009), which complicates the interpretation of the pharmacokinetic analysis by 
assuming an initial concentration in plasma that is not an accurate representation of the 
percentage dose that reached the central compartment.  Goodness of the model fit seems 
to provide reassurance that this was not a significant concern in our studies. 
 
Additionally, when considering our organ localization analysis based on imaging and 
quantitative content data, the applicability of our conclusions is limited by the fact that 
we only collected organs at the 24-hour data point. However, based on the results 
showing that IR820 and IRPDcov have much slower distribution and elimination profiles 
than ICG, we would not expect that additional data collected in the range of one hour 
after injection would reveal any further information than that provided to us by the 24-
hour time point. This time point allows us to clearly highlight the differences between 
agents, and provides us with information within a clinically relevant theranostic window.  
The same could be said for our plasma data and the selection of four time points in terms 
of whether there are sufficiently representative. Although of course obtaining as many 
samples for as many time points as possible is always desirable, one of the central tenets 
of science is the ability to prioritize while designing an experiment. Our goal should be to 
design an experiment that allows us to obtain the most relevant pieces of information, i.e., 
those which will help us answer our starting questions. We are confident that the data we 
have collected provides a good insight into the behavior of these agents in an in vivo 
model. 
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6.4. Summary 
Biodistribution and pharmacokinetic studies of IRPDcov, IR820, and ICG in mice show 
that IRPDcov is a feasible alternative to IR820 for in vivo imaging, and that it 
demonstrates an improved pharmacokinetic profile over the free dye form as well as over 
the commonly used near-infrared dye ICG. The IRPDcov conjugate has different organ 
localization than free IR820, with potential reduced accumulation in the kidneys and 
significantly lower (p<0.05) accumulation in the lungs. Both IRPDcov and IR820 had 
entered fecal elimination pathways to a lesser extent than ICG after 24 hours, with larger 
overall recovered percent injected dose from major organs and plasma compared to ICG. 
Plasma IRPDcov concentration was significantly higher than that of IR820 for time 
points after the initial 15 minutes post-injection, and both IR820 formulations (conjugate 
and free form) showed higher plasma concentrations than ICG at all sampling points after 
injection. When plasma concentration was modeled using a two-compartment approach, 
the conjugate demonstrated a biphasic profile with significantly longer distribution and 
elimination half-lives, longer mean plasma residence time, larger overall exposure as 
indicated by AUC, and slower clearance rate compared to either IR820 or ICG. The 
nanosize nature of our conjugate, as well as surface and charge characteristics provided 
by the presence of PEG, is likely to be responsible for these differences. The use of 
IRPDcov conjugates could provide wider dye in vivo availability windows for theranostic 
applications. 
 
 
124 
 
Chapter 6 References 
 
Achilefu, S. and R. B. Dorshow (2002). Dynamic and Continuous Monitoring of Renal 
and Hepatic Functions with Exogenous Markers, Springer. 
 
Achilefu, S., R. B. Dorshow, et al. (2000). Novel receptor-targeted fluorescent contrast 
agents for in vivo tumor imaging. Invest Radiol 35(8): 479-485. 
 
Albanese, A., P. S. Tang, et al. (2012). The effect of nanoparticle size, shape, and surface 
chemistry on biological systems. Annu Rev Biomed Eng 14: 1-16. 
 
Arvizo, R. R., O. R. Miranda, et al. (2011). Modulating pharmacokinetics, tumor uptake 
and biodistribution by engineered nanoparticles. PLoS One 6(9): e24374. 
 
Bauer, L. (2008). Applied Clinical Pharmacokinetics. New York, NY, McGraw Hill. 
 
Berezhkovskiy, L. M. (2009). Determination of mean residence time of drug in plasma 
and the influence of the initial drug elimination and distribution on the calculation 
of pharmacokinetic parameters. J Pharm Sci 98(2): 748-762. 
 
Cho, K., X. Wang, et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. 
Clin Cancer Res 14(5): 1310-1316. 
 
de Chermont, Q. L., C. Chaneac, et al. (2007). Nanoprobes with near-infrared persistent 
luminescence for in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 104(22): 9266-
9271. 
 
Desmettre, T., J. M. Devoisselle, et al. (2000). Fluorescence properties and metabolic 
features of indocyanine green (ICG) as related to angiography. Surv Ophthalmol 
45(1): 15-27. 
 
Dhanikula, A. B., D. R. Singh, et al. (2005). In vivo pharmacokinetic and tissue 
distribution studies in mice of alternative formulations for local and systemic 
delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles. Curr Drug 
Deliv 2(1): 35-44. 
 
 European Commission, Research & Innovation - Health Department. (2010). Of Mice 
and Men – Are Mice Relevant Models for Human Disease? London, UK. 
Available at: http://ec.europa.eu/research/health/pdf/summary-report-
25082010_en.pdf. Accessed September 24, 2012. 
 
Fournier, R. L. (2007). Basic Transport Phenomena in Biomedical Engineering. New 
York, NY, Taylor & Francis. 
 
Hoff, J. (2000). Methods of blood collection in the mouse. Lab Animal 29(10): 47-53. 
125 
 
 
Li, S. D. and L. Huang (2008). Pharmacokinetics and biodistribution of nanoparticles. 
Mol Pharm 5(4): 496-504. 
 
Liu, D., A. Mori, et al. (1992). Role of liposome size and RES blockade in controlling 
biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys 
Acta 1104(1): 95-101. 
 
Macon, M. B., L. R. Villanueva, et al. (2011). Prenatal perfluorooctanoic acid exposure 
in CD-1 mice: low-dose developmental effects and internal dosimetry. Toxicol Sci 
122(1): 134-145. 
 
Moghimi, S. M., A. C. Hunter, et al. (2012). Factors controlling nanoparticle 
pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol 
Toxicol 52: 481-503. 
 
Mordon, S., J. M. Devoisselle, et al. (1998). Indocyanine green: physicochemical factors 
affecting its fluorescence in vivo. Microvasc Res 55(2): 146-152. 
 
Prajapati, S. I., C. O. Martinez, et al. (2009). Near-infrared imaging of injured tissue in 
living subjects using IR-820. Mol Imaging 8(1): 45-54. 
 
Rajagopalan, R., P. Uetrecht, et al. (2000). Stabilization of the optical tracer agent 
indocyanine green using noncovalent interactions. Photochem Photobiol 71(3): 
347-350. 
 
Saxena, V., M. Sadoqi, et al. (2006). Polymeric nanoparticulate delivery system for 
Indocyanine green: biodistribution in healthy mice. Int J Pharm 308(1-2): 200-
204. 
Truskey, G. A., F. Yuan, et al. (2009). Transport Phenomena in Biological Systems. 
Upper Saddle River, NJ, Pearson Prentice Hall. 
 
van Vlerken, L. E., T. K. Vyas, et al. (2007). Poly(ethylene glycol)-modified nanocarriers 
for tumor-targeted and intracellular delivery. Pharm Res 24(8): 1405-1414. 
 
Wolfensohn, S. and M. Lloyd (2003). Handbook of Laboratory Animal Management and 
Welfare. Oxford, UK, Wiley-Blackwell. 
 
Yaseen, M. A., J. Yu, et al. (2009). Biodistribution of encapsulated indocyanine green in 
healthy mice. Mol Pharm 6(5): 1321-1332. 
 
Zuegge, J., G. Schneider, et al. (2001). Prediction of hepatic metabolic clearance: 
comparison and assessment of prediction models. Clin Pharmacokinet 40(7): 553-
563. 
 
126 
 
CHAPTER 7: OVERALL DISCUSSION AND CONCLUSIONS 
The development of multifunctional agents for cancer management is a rapidly growing 
field which can result in improved diagnosis and therapy for patients with cancer. Recent 
developments in nanotechnology have fueled the growth of theranostics research, 
because nanoformulations have unique characteristics that make them well-suited to 
customized therapy approaches and multimodal applications. Nanosize therapeutic and 
diagnostic agents can be tailored to a specific application by manipulating their size, 
shape, surface characteristics, and other physiochemical properties, resulting in 
personalized strategies to treat disease. This frame of thought involves the customization 
of diagnostic and therapeutic approaches to a specific disease process, and is especially 
relevant in disorders such as cancer, which is very heterogeneous and encompasses a 
large spectrum of alterations in cellular processes and behavior. Customizable medicine, 
along with the combination of diagnostic and therapeutic approaches to improve 
management such as the ability to use imaging to guide therapy, opens the door to a new 
era in patient care.   
 
Near-infrared dyes can be used as theranostic agents in cancer management based on 
their optical imaging and localized hyperthermia capabilities, however, they have 
important limitations which limit their applicability for theranostic use, especially in 
terms of photobleaching, in vivo instability and non-specific biodistribution (Frangioni, 
2003). Another concern based on these disadvantages is the ability to provide convenient 
timing for combined imaging and therapy. In our work, we studied the properties of the 
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cyanine dye IR820, and provided the first detailed report of its potential for use in 
theranostics. We studied the applications of IR820 in optical imaging and hyperthermia, 
and we prepared nanoconjugate formulations that retain or improve upon these 
theranostic capabilities.  
 
We chose to study the cyanine dye IR820 because of its chemical structure. IR820 is 
structurally similar to indocyanine green (ICG), which is a clinically approved cyanine 
dye. ICG can be used in imaging and hyperthermia applications, so we expected IR820 to 
have similar multi-functionality. On the other hand, we hypothesized that the presence of 
a chlorohexene ring in IR820 which is absent in ICG could mean that IR820 would have 
improved stability as well as more amenability to conjugation. Our results showed that 
IR820 has optical and thermal generation properties similar to indocyanine green, but 
with improved in vitro and in vivo stability. The fluorescent emission of IR820 has a 
lower quantum yield than ICG, but less dependence of the emission peak location on 
concentration. This predictability of peak location for IR-820 could facilitate the design 
of imaging systems targeting IR-820 emission wavelengths. Additionally, IR820 
demonstrated higher stability than ICG in aqueous solution under all temperature and 
light conditions, with degradation half-times approximately double those of ICG for a 
given experimental condition. IR820 is still susceptible to photobleaching, but less so 
than ICG. In hyperthermia applications, IR820 generated lower peak temperatures than 
ICG (4-9%) after three-minute laser exposure. However, it was still able to cause 
temperature increases into the desired hyperthermia range of 40-43°C that is able to 
selectively impact tumor cell growth. There was no significant difference in hyperthermia 
128 
 
cytotoxicity between IR820 and ICG, with both dyes causing cancer cell growth 
inhibition at 5 µM and cell killing at 10 µM upon laser exposure. Free IR820 can be used 
for in vitro and in vivo optical imaging, with a strong detectable signal still present in rats 
24 hours after i.v. injection, a plasma half-life in the order of hours, and primary 
biodistribution to the liver, lung, and kidneys.  Our study shows that IR820 is a feasible 
agent in experimental models of imaging and hyperthermia, and could be an alternative to 
ICG when greater stability, longer image collection times, or more predictable peak 
locations are desirable. 
 
Even though IR820 is a promising theranostic agent, clinical translation of NIR-imaging 
and hyperthermia approaches in cancer must overcome the challenges presented by free 
dye formulations in terms of plasma circulation times and non-specific biodistribution. 
Nanotechnology provides some opportunities to improve in vivo stability and target 
delivery. Physicochemical characteristics of nanoformulations such as size, surface 
charge, and surface characteristics can be modified to alter their interactions with 
circulating immune system components and with cellular membranes. In terms of the 
behavior of nanoformulations in vivo, it has been shown that nanosize agents are less 
susceptible to reticuloendothelial system clearance and have better penetration into 
tissues and cells than larger size agents (Brigger et al., 2002; Xu et al., 2006). 
Nanoformulations can also take advantage of the enhanced permeability and retention 
(EPR) effect thanks to their size, and thus are inherently able to accumulate preferentially 
at tumor sites through passive targeting (Iyer et al., 2006).  
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We chose to conjugate IR820 with polyethylene glycol (PEG) to create a 
nanoformulation with additional desirable properties in terms of in vivo behavior, besides 
the advantages imparted by its nano nature. Research has shown that the presence of PEG 
in nanoformulations can reduce capture by the immune system, and result in improved 
plasma circulation times (Harris et al., 2001). Longer exposure to the theranostic agent 
provides a wider window of opportunity for diagnosis and therapy, and allows more 
flexibility in terms of timing, one with respect to the other, as needed for a specific 
application. Additionally, PEG can be used as a linker to conjugate other moieties and 
impart new functionality such as specific targeting. 
 
The first step in exploring the potential of an IR820/PEG nanoconjugate for theranostic 
applications was to create ionic conjugates and determine if the optical and thermal 
generation properties of IR280 were preserved as part of a conjugate lattice. We 
successfully prepared ionic IR820-PEG-diamine nanoconjugates (IRP820-DNCs) which 
were approximately 50 nm diameter in SEM images, and had a zeta potential of 2.0±0.9 
mV. IRPDNCs showed enhanced cellular internalization in SKOV-3, MES-SA, and Dx5 
cells for imaging purposes compared to the free dye, possibly due to osmotic stress on 
cellular membranes induced by the proximity of PEG. Cytotoxicity studies in SKOV-3, 
MES-SA and Dx5 cancer cell lines showed comparable cytotoxicity of IR820-PDNCs 
versus free IR820 after 24 hours. IR820-PDNCs were able to produce hyperthermic cell 
growth inhibition in all three cancer cell lines after excitation with laser, and they 
significantly enhanced hyperthermia-mediated cytotoxicity in MES-SA and Dx5 
compared to hyperthermia using free dye. We concluded that this formulation can 
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potentially provide an advantage over the use of free agents by enhancing cell uptake, 
allowing simultaneous co-localization of imaging and therapy, and accentuating the 
cytotoxic effect of hyperthermia.  
 
After proving that IR820 retained its ability to generate heat and fluoresce when 
interacting in close proximity with PEG as part of an ionic formulation, we hypothesized 
that modifying this formulation to create covalent conjugates could improve on the 
stability of the lattice and result in nanosize conjugates that may be used in in vivo 
applications with improved pharmacokinetic profiles compared to the free dye. Thus, we 
prepared and characterized covalent conjugates of IR820 and PEG-diamine (IRPDcov). 
IRPDcov retained the ability to fluoresce after 785-nm excitation and to be used for in 
vitro optical imaging of cancer cells as well as in vivo imaging. In vitro cellular 
internalization was not as large as for ionic conjugates, but it was still larger than for free 
dye. IRPDcov also retained the heat-generation ability of IR820 upon exposure to 808-
nm laser, and was significantly more stable than IR820 in aqueous solution over a period 
of 72 hours. In mouse plasma samples, IRPDcov and IR820 when compared to ICG 
demonstrated significantly longer (p<0.05) distribution half-lives, elimination half-lives, 
and area-under-the-curve values. For IRPDcov, the area under the kinetic curve was 
almost 16 times larger than that of ICG, and approximately double that of IR820, 
indicating significantly longer overall exposure to the probe. This could pose an 
advantage in therapeutic probe applications such as hyperthermia or drug delivery. 
Regarding organ biodistribution, both IR820 and IRPD showed a very strong signal in the 
liver and lower-intensity signal in the kidneys 24 hours after i.v. injection, whereas the 
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predominant signal for ICG was weak and located in the intestines, demonstrating a much 
more rapid GI elimination. IRPDcov was different from IR820 in that the latter showed a 
signal in the lungs, which was not present in IRPDcov subjects. This indicates that 
IRPDcov may have been able to escape detection by alveolar macrophages. Our results 
are consistent with existing literature reports of increased half-life and decreased immune 
system uptake for PEGylated nanoformulations (Albanese et al., 2012; Arvizo et al., 
2011; Brigger et al., 2002). We concluded that IRPDcov conjugates have potential 
applications as dual imaging-hyperthermia agents, are more stable in aqueous solution 
than IR820, can enhance the effect of hyperthermia in MES-SA and Dx5 cells, improve 
cell uptake with respect to free dye, and can provide improved theranostic windows in 
vivo. 
 
The conjugation of PEG-diamine with a NIR dye provides a multifunctional delivery 
vector whose localization can be monitored with noninvasive techniques and that may 
also serve for guided hyperthermia cancer treatments. Future work should focus on 
studying the biodistribution of these conjugates in tumor-bearing animals in order to 
determine in vivo tumor uptake, as well as on the design and optimization of minimally 
invasive in vivo methods for combined imaging and hyperthermia, possibly through fiber 
optic technology. Additionally, there may be opportunities for active targeting of these 
conjugates.  Terminal functional groups in PEG may be conjugated via amide bonding or 
bisulfide bridges with proteins, peptides, aptamers, and other small moieties for active 
targeting (van Vlerken et al., 2007). Functionalization can create specific interactions 
with cell surface receptors and result in enhanced uptake at sites of interest, with the 
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subsequent potential for customization of cancer therapies. Finally, it may also be 
possible to incorporate other therapeutic agents, such as chemotherapy drugs during 
nanoconjugate formulation in order to encapsulate them within the nanoplexes. This 
would result in a versatile multifunctional agent providing imaging, chemotherapy, and 
hyperthermia capabilities. Image-guided therapy using IR820 conjugates shows promise 
for clinical translation as it can be coupled with minimally invasive light delivery 
techniques such as endoscopic or orthoscopic approaches. 
We believe that there are many unexplored possibilities for customizable IR820 
conjugates besides the ones discussed in this dissertation which focused on PEG-
containing conjugates. Researchers are actively pursuing the use of IR820 in different 
applications, including the use of IR820 as a blood pool contrast agent, the preparation of 
conjugates of IR820 with photodynamic therapy agents, and the incorporation of IR820 
into multifunctional nanoparticles (Pandey et al., 2008; Prajapati et al., 2009; Thierry et 
al., 2009). Our group also continues to explore possible theranostic applications of IR820. 
For instance, one of our formulations covalently coupled IR820 with chitosan to form 
IR820-chitosan conjugates that also enhanced hyperthermic cell growth inhibition in 
MES-SA and Dx5 cells after 808-nm laser exposure, and can be used for in vitro and in 
vivo imaging. In a rat model, IR820-chitosan conjugates were eliminated through the 
gastrointestinal tract, with potential applications as contrast agents and gene delivery 
vehicles passively targeted to the digestive system. These results highlight the possibility 
of developing IR820 conjugates for different applications based on the identity of the 
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linker or conjugated moiety, thus creating opportunities for customizable theranostic 
agents and furthering the vision of personalized medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
Chapter 7 references 
 
Albanese, A., P. S. Tang, et al. (2012). The effect of nanoparticle size, shape, and surface 
chemistry on biological systems. Annu Rev Biomed Eng 14: 1-16. 
 
Arvizo, R. R., O. R. Miranda, et al. (2011). Modulating pharmacokinetics, tumor uptake 
and biodistribution by engineered nanoparticles. PLoS One 6(9): e24374. 
 
Brigger, I., C. Dubernet, et al. (2002). Nanoparticles in cancer therapy and diagnosis. 
Adv. Drug Delivery Rev. 54(5): 631-651. 
 
Frangioni, J. V. (2003). In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. 
Biol. 7(5): 626-634. 
 
Harris, J. M., N. E. Martin, et al. (2001). Pegylation: a novel process for modifying 
pharmacokinetics. Clin. Pharmacokinet. 40(7): 539-551. 
 
Iyer, A. K., G. Khaled, et al. (2006). Exploiting the enhanced permeability and retention 
effect for tumor targeting. Drug Discov Today 11(17-18): 812-818. 
 
Pandey, R. K., N. James, et al. (2008). Cyanine-based compounds for tumor imaging 
with and without photodynamic therapy. Top Heterocycl Chem 14: 41-74. 
 
Prajapati, S. I., C. O. Martinez, et al. (2009). Near-infrared imaging of injured tissue in 
living subjects using IR-820. Mol Imaging 8(1): 45-54. 
 
Thierry, B., F. Al-Ejeh, et al. (2009). Multifunctional core-shell magnetic cisplatin 
nanocarriers. Chem Commun (Camb)(47): 7348-7350. 
 
van Vlerken, L. E., T. K. Vyas, et al. (2007). Poly(ethylene glycol)-modified nanocarriers 
for tumor-targeted and intracellular delivery. Pharm Res 24(8): 1405-1414. 
 
Xu, Z. P., Q. H. Zeng, et al. (2006). Inorganic nanoparticles as carriers for efficient 
cellular delivery. Chem. Eng. Sci. 61(3): 1027-1040. 
 
 
 
135 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
136 
 
APPENDIX I. PERMISSION FROM AMERICAN SCIENTIFIC PUBLISHERS 
 
137 
 
 
138 
 
 
 
139 
 
APPENDIX II. PERMISSION FROM DECKER PUBLISHING 
 
140 
 
VITA 
 
ALICIA FERNANDEZ-FERNANDEZ 
 
    Born, Asturias, Spain 
 
1994-1997    Diploma in Physical Therapy 
Universidad de Oviedo 
Oviedo, Spain 
 
2000-2001    B.S., Health Sciences 
    Florida International University 
Miami, Florida 
 
2001-2002   M.S., Physical Therapy 
Florida International University 
Miami, Florida 
 
2003-2007    B.S., Biomedical Engineering 
    Florida International University 
Miami, Florida 
 
2006-2010   Doctor of Physical Therapy 
    Nova Southeastern University 
    Fort Lauderdale, Florida 
  
2007-2013   Doctoral Candidate, Biomedical Engineering 
Florida International University 
Miami, Florida 
 
2011-present    Assistant Professor, Physical Therapy Department 
Nova Southeastern University 
    Fort Lauderdale, Florida 
 
 
PUBLICATIONS AND PRESENTATIONS (ABRIDGED LIST) 
 
Fernandez-Fernandez, A., R. Manchanda, D.A. Carvajal, T. Lei, and A.J. 
McGoron. Covalent IR820-PEG diamine conjugates: Characterization and in vivo 
biodistribution. Proceedings of SPIE BiOS 2013, in press. 
 
Fernandez-Fernandez, A., R. Manchanda, T. Lei, Y. Tang, S.Z. Raza Kazmi, and A.J. 
McGoron.  Comparative study of optical and heat generation properties of IR820 and 
indocyanine green. Molecular Imaging. 2012 Apr 1;11(2):99-113. PubMed ID: 22469238  
 
141 
 
Fernandez-Fernandez, A., R. Manchanda, and A.J. McGoron. Theranostic applications of 
nanomaterials in cancer: Image-guided therapy and multifunctional platforms. Applied 
Biochemistry and Biotechnology. 2011; 165(7-8):1628-51. PubMed ID: 21947761.  
 
Fernandez-Fernandez A, R. Manchanda, T. Lei, and A.J. McGoron. Preparation and 
Characterization of Covalent IR820-PEG Diamine Conjugates. BMES 2012, October 24-
27, Atlanta, GA. Poster presentation. 
 
Fernandez-Fernandez, A., R. Manchanda, T. Lei, S. Srinivasan, and 
A.J. McGoron. Covalent IR820-PEG diamine nanoconjugate for imaging and 
hyperthermia. NanoFlorida 2012, September 28-29, Tampa, FL. Oral presentation. 
Received presentation award. 
 
Fernandez-Fernandez, A., R. Manchanda, S. Srinivasan, T. Lei, D. Carvajal, and 
A.J. McGoron. IR820-chitosan conjugates for imaging and hyperthermia. SNM 2012, 
June 9-13, Miami, FL.  Proceedings citation: J Nucl Med. 2012; 53 (Suppl. 1):1172 
 
Fernandez-Fernandez, A., R. Manchanda,  T. Lei, S. Srinivasan, and A.J.McGoron. 
IR820 Conjugates for Image-Guided Cancer Therapy. World Congress on Medical 
Physics and Biomedical Engineering, Beijing, China. May 26-31, 2012. IFMBE 
proceedings, volume 39, in press, ISBN 978-3-642-29304-7. Presented by AJM. 
Lei, T., S. Srinivasan, Y. Tang, R. Manchanda, A. Nagesetti, A. Fernandez-
Fernandez, and A.J. McGoron. Comparing cellular uptake and cytotoxicity of targeted 
drug carriers in cancer cell lines with different drug resistance mechanisms. 
Nanomedicine:NBM. 2011;7(3):324-332. PubMed ID: 21094277. 
 
Manchanda, R., A. Fernandez-Fernandez, D.A. Carvajal, T. Lei, Y. Tang, and A.J. 
McGoron. Nanoplexes for cell imaging and hyperthermia: in vitro studies. J Biomed 
Nanotechnol. 2012, 8(4):686-694. PubMed ID: 22852478 
 
Manchanda, R., A. Fernandez-Fernandez, A. Nagesetti, and A.J. McGoron. Preparation 
and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with 
simultaneous incorporation of chemotherapeutic and thermo-optical agents.  J Colloids 
Surf B Biointerfaces. 2010;75(1):260-7. Pubmed ID: 19775872. 
 
Srinivasan, S., R. Manchanda, A. Fernandez-Fernandez, T. Lei, A.J. McGoron. Near-
infrared ﬂuorescing IR820-chitosan conjugate for multifunctional cancer theranostic 
applications. J Photochem Photobiol B, in press. 
 
Tang, Y., T. Lei, R. Manchanda, A. Nagesetti, A. Fernandez-Fernandez, and A.J. 
McGoron. Simultaneous delivery of chemotherapeutic and thermal-optical agents to 
cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res. 2010; 
27(10):2242-2253. PubMed ID: 20694526. 
